<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of acute chemotherapy-related diarrhea</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of acute chemotherapy-related diarrhea</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of acute chemotherapy-related diarrhea</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carole Macaron, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Reed E Drews, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 14, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2016648847"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Most chemotherapeutic agents target rapidly dividing cells, and effects on these cells within the gastrointestinal tract can lead to a variety of symptoms. Diarrhea caused by chemotherapy, referred to here as chemotherapy-related diarrhea (CRD), is a serious and potentially life-threatening complication of a wide variety of chemotherapy drugs and hospital admission is frequently needed for adequate supportive care. CRD may also result in treatment delays and diminished compliance, which may compromise long-term outcomes.</p><p>This topic will review the management of CRD. The pathogenesis of CRD, predictive markers for fluoropyrimidine- and irinotecan-related diarrhea, and management of diarrhea in patients receiving immune checkpoint inhibitors are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Diarrhea'</a> and  <a class="medical medical_review" href="/z/d/html/138429.html" rel="external">"Immune checkpoint inhibitor colitis"</a>.)</p><p class="headingAnchor" id="H394781640"><span class="h1">AGENTS MOST COMMONLY ASSOCIATED WITH DIARRHEA</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conventional cytotoxic agents</strong> – CRD is a common problem in cancer patients receiving systemic antineoplastic therapy, and is most often described with fluoropyrimidines (particularly <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> [FU] and <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a>) and <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>. Diarrhea is often the dose-limiting and major toxicity of regimens containing a fluoropyrimidine with irinotecan. The frequency of severe (grade 3 or 4  (<a class="graphic graphic_table graphicRef65649" href="/z/d/graphic/65649.html" rel="external">table 1</a>)) diarrhea with these agents ranges from 5 to 44 percent, and rates vary according to the dose, the specific agents administered, and the schedule of administration. (See  <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Fluorouracil'</a> and  <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Irinotecan'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecularly targeted agents</strong> – In addition to conventional cytotoxic drugs, such as fluoropyrimidines and <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>, several molecularly targeted agents are also associated with high rates of CRD:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For many tyrosine kinase inhibitors (TKIs), such as <a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">afatinib</a>, <a class="drug drug_general" data-topicid="95046" href="/z/d/drug information/95046.html" rel="external">ceritinib</a>, <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a>, <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">lapatinib</a>, <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a>, and <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, and phosphatidylinositol 3-kinase (PI3K) inhibitors (eg, <a class="drug drug_general" data-topicid="121400" href="/z/d/drug information/121400.html" rel="external">alpelisib</a>), diarrhea is second only to rash as the most common toxicity. Diarrhea develops in one-half or more of treated patients, although the incidence of severe (grade 3 or 4) diarrhea is lower than with conventional cytotoxic agents. Diarrhea is especially common with ceritinib, <a class="drug drug_general" data-topicid="114008" href="/z/d/drug information/114008.html" rel="external">neratinib</a>, and afatinib, occurring in 75 to 95 percent of treated patients, but severe in only 2 to 16 percent. (See  <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Small molecule EGFR inhibitors'</a> and  <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Small molecule inhibitors of VEGFR'</a> and  <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Lapatinib, pertuzumab, neratinib, and tucatinib'</a> and  <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'ALK inhibitors'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) rarely cause severe diarrhea when used as monotherapy but can increase the incidence of severe diarrhea when combined with cytotoxic chemotherapy. (See  <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Anti-EGFR monoclonal antibodies'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The antiangiogenic agent <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a>, which is a recombinant fusion protein of the vascular endothelial growth factor (VEGF) binding portions of the VEGF receptors 1 and 2 fused to the Fc portion of human immunoglobulin G1 (IgG1), increased severe diarrhea by 10 percent when added to FOLFIRI (<a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> plus <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> and short-term infusional FU) chemotherapy [<a href="#rid1">1</a>]. When added to FOLFOX (<a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> plus leucovorin and short-term infusional FU) chemotherapy, aflibercept increased the incidence of severe diarrhea by 8 percent [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Checkpoint inhibitor immunotherapy with the cytotoxic T lymphocyte associated antigen 4 (CTLA4) inhibitor <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> and programmed cell death protein 1 (PD-1) inhibitors <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> and <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, causes an immune-mediated colitis that is severe in up to 9 percent of treated patients. The anti-programmed cell death ligand 1 (PD-L1) antibodies <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a> and <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">durvalumab</a> can also cause diarrhea, but severe diarrhea is rare [<a href="#rid3">3,4</a>]. (See  <a class="medical medical_review" href="/z/d/html/138429.html" rel="external">"Immune checkpoint inhibitor colitis"</a>.)</p><p></p><p class="headingAnchor" id="H2936699064"><span class="h1">OVERVIEW OF MECHANISMS</span><span class="headingEndMark"> — </span>In general, most cases of CRD occur through three different pathophysiologic mechanisms: increased secretion of electrolytes, caused by luminal secretagogues or reduced absorptive capacity (due to surgery or epithelial damage caused by the chemotherapy drugs themselves), called secretory diarrhea; increased intraluminal osmotic substances, leading to osmotic diarrhea; or altered gastrointestinal motility. In general, secretory diarrhea characteristically continues despite fasting, is associated with stool volumes &gt;1 L/day, and occurs day and night, in contrast to osmotic diarrhea, in which these characteristics are uncommon. (See  <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Pathogenesis/mechanisms'</a>.)</p><p>Briefly:</p><p class="bulletIndent1"><span class="glyph">●</span>Both <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> (FU) and <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> can cause damage to the intestinal mucosa, leading to loss of epithelium and secretory diarrhea [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 10 percent of patients being treated with FU have decreased expression of the enzyme lactase in their intestinal brush border, leading to lactose intolerance and causing osmotic diarrhea [<a href="#rid6">6,7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Early onset diarrhea with <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> (ie, during or within several hours of drug infusion) is cholinergically mediated (ie, related to increased motility) [<a href="#rid8">8</a>]. By contrast, late irinotecan-associated diarrhea is not cholinergically mediated but, instead, appears to be multifactorial, with contributions from dysmotility and secretory factors, as well as a direct toxic effect on the intestinal mucosa. (See  <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Risk with conventional cytotoxic agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diarrhea caused by tyrosine kinase inhibitors (TKIs) occurs through multiple mechanisms. Increased chloride secretion caused by dysregulation of the epidermal growth factor receptor (EGFR) signaling pathway, colonic crypt damage, gut dysmotility, and alteration in gut microbiota have been proposed.</p><p></p><p>By contrast, the diarrhea caused by checkpoint inhibitor immunotherapy with the cytotoxic T lymphocyte associated antigen 4 (CTLA4) inhibitor <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> and programmed cell death protein 1 (PD-1) inhibitors <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> and <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> is immune mediated. This subject is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/138429.html" rel="external">"Immune checkpoint inhibitor colitis"</a>.)</p><p class="headingAnchor" id="H1780141228"><span class="h1">OVERVIEW OF CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>CRD typically begins with an increasing frequency of bowel movements and/or a loosening of stool consistency. Excessive gas and/or intestinal cramping commonly accompanies CRD. As the CRD progresses, it can become severe, with frequent watery stools. CRD can be debilitating and, in some cases, life-threatening. Findings in such patients include volume depletion, acute kidney injury, and electrolyte disorders such as hypokalemia, metabolic acidosis, and depending on water intake, hyponatremia (increased water intake that cannot be excreted because of the hypovolemic stimulus to the release of antidiuretic hormone) or hypernatremia (insufficient water intake to replace losses). Infection, including life-threatening sepsis, can result due to breach of the intestinal mucosa, which is worsened in the setting of chemotherapy-induced immunosuppression. (See  <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Clinical manifestations'</a>.)</p><p>Given the risk for dehydration and infection, severe CRD frequently requires hospital admission for adequate supportive care [<a href="#rid9">9-12</a>]. Other sequelae of CRD include increased cost of care, reduced quality of life, treatment delays, and diminished compliance with treatment regimens, which may compromise long-term outcomes if the chemotherapy is being administered with curative intent [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H3296160038"><span class="h1">CLINICAL ASSESSMENT</span><span class="headingEndMark"> — </span>The severity of CRD is often described using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grades; the latest version (v5.0) is outlined in the table  (<a class="graphic graphic_table graphicRef65649" href="/z/d/graphic/65649.html" rel="external">table 1</a>). Severity is determined by the number of stools per day or an increase in ostomy output compared with baseline, the need for hospitalization, and the effect on activities of self-care. It is critical to ascertain the patient's baseline bowel pattern when grading the severity of CRD. Although adequate for study purposes, these criteria have been criticized because they do not take into account the volume or the duration of diarrhea [<a href="#rid13">13</a>]. Other validated CRD measurement scales have been developed but are not in general use [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H655800720"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>A general approach to evaluation and management of CRD is outlined in the algorithm  (<a class="graphic graphic_algorithm graphicRef64251" href="/z/d/graphic/64251.html" rel="external">algorithm 1</a>), which is based on several published guidelines [<a href="#rid13">13,15,16</a>].</p><p class="headingAnchor" id="H3422348735"><span class="h3">History and physical examination</span><span class="headingEndMark"> — </span>Evaluation of the patient with CRD begins with a history to determine the severity according to the NCI CTCAE grades  (<a class="graphic graphic_table graphicRef65649" href="/z/d/graphic/65649.html" rel="external">table 1</a>). The volume and duration of diarrhea should also be determined, and the history should include questions concerning foods or drugs that might play a contributory role (which are usually avoided in patients with CRD)  (<a class="graphic graphic_table graphicRef57475" href="/z/d/graphic/57475.html" rel="external">table 2</a>) [<a href="#rid13">13</a>]. A recent initiation of proton pump inhibitors, nonsteroidal anti-inflammatory agents, antibiotics, or laxatives and/or a stool softener (eg, to prevent opioid-induced constipation) can all cause or contribute to diarrhea.</p><p>Because mucosal injury caused by chemotherapy may lead to a temporary lactase deficiency, the ingestion of milk-containing foods may be an important trigger for diarrhea and should be specifically queried. (See  <a class="medical medical_review" href="/z/d/html/2542.html" rel="external">"Lactose intolerance and malabsorption: Clinical manifestations, diagnosis, and management"</a>.)</p><p>It should also be appreciated that other factors can contribute to diarrhea in cancer patients treated with chemotherapy, and the history should be geared to exploring the possibility of intestinal infection (eg, <em>Clostridioides</em> [formerly <em>Clostridium</em>]<em> difficile</em>, especially in a patient with prior<em> C. difficile </em>infection), abdominopelvic radiation therapy, prior intestinal resection, malabsorption, intake of excess laxatives or artificial sweeteners, and stool impaction. Patients who have anorexia, abdominal bloating or pain, and frequent soft or loose stool, as opposed to watery diarrhea, may have overflow diarrhea (ie, passage of stool around impacted stool). The presence of fever, dizziness, or abdominal pain should raise concern for a possible complication, such as sepsis or bowel obstruction. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Patients who have an ileostomy are at increased risk for severe diarrhea and dehydration from copious watery ileostomy output. Average output for the ileostomy patient ranges from 500 to 1300 mL a day. Ileostomy effluent contains significant amounts of sodium and potassium. This daily fluid loss places the ileostomy patient at greater risk for dehydration and electrolyte disorders, especially during episodes of increased output. Patients who have an ileostomy are frequently on a baseline regimen of <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> to maintain thick ileostomy output and should be carefully queried about loperamide use and oral fluid intake. (See  <a class="medical medical_review" href="/z/d/html/1384.html" rel="external">"Ileostomy or colostomy care and complications", section on 'Ileostomy patients'</a>.)</p><p>A careful physical examination should be performed to assess for signs of volume depletion (eg, reduced skin turgor, hypotension, which may be primarily orthostatic, and low jugular venous pressure) (see  <a class="medical medical_review" href="/z/d/html/2298.html" rel="external">"Etiology, clinical manifestations, and diagnosis of volume depletion in adults"</a>) and infection.</p><p class="headingAnchor" id="H3132968079"><span class="h3">Investigations</span><span class="headingEndMark"> — </span>Laboratory testing should address both the complications and causes of CRD. These include a complete blood count and a standard chemistry screen including magnesium. For patients with severe (grade 3 or 4) diarrhea, persistent mild to moderate (grade 1 or 2) diarrhea, or diarrhea accompanied by neutropenia, fever, or blood in the stools, cultures of blood and stool, and diagnostic testing for toxin-producing strains of <em>C. difficile</em> are indicated. (See <a class="local">'Infectious causes'</a> below.)</p><p>Radiographic imaging is not typically needed in most patients with acute CRD. However, for patients who have fever, peritoneal signs, or bloody diarrhea, abdominal imaging (most typically computed tomography [CT]) can be important to identify potential complications, such as bowel perforation, abscess, or neutropenic enterocolitis, or to rule out causes of diarrhea not associated with chemotherapy (eg, bowel ischemia). Surgical consultation may also be needed in these cases. Abdominal radiographs, which can document the extent of stool, are useful in cases of suspected overflow diarrhea.</p><p>Endoscopy is not indicated in the vast majority of cases but should be considered for refractory cases and for patients who develop chronic diarrhea (ie, diarrhea that persists throughout the entire chemotherapy cycle) or bloody diarrhea. (See <a class="local">'Lymphocytic colitis'</a> below and <a class="local">'Management of refractory patients'</a> below.)</p><p class="headingAnchor" id="H1173989123"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Patients who develop diarrhea during chemotherapy may also suffer from organic causes of diarrhea, which may or may not be related to the chemotherapy and should not be overlooked. These include small intestinal bacterial overgrowth (SIBO), fat or bile acid malabsorption, intake of excess quantities of <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">sorbitol</a> or lactose intolerance, inflammatory and infectious causes, and stool impaction.</p><p class="headingAnchor" id="H3855904972"><span class="h3">Small intestinal bacterial overgrowth as a cause of fat and carbohydrate malabsorption</span><span class="headingEndMark"> — </span>Although difficult to diagnose with certainty, SIBO has been reported in immunosuppressed patients after bowel resection surgery and following pelvic radiation therapy [<a href="#rid17">17-19</a>]. SIBO causes fat malabsorption through bacterial deconjugation of bile acids and carbohydrate malabsorption secondary to luminal degradation of carbohydrates by the gut bacteria. Patients often report abdominal discomfort, flatulence, and foul-smelling, oily, and difficult to flush stools. Deficiencies in lipid-soluble vitamins and in vitamin B12 (consumed by the gut bacteria), as well as elevated folate levels (synthesized by the gut microbiota), are indirect biochemical indices of SIBO [<a href="#rid20">20</a>]. The diagnosis of SIBO most often relies on the use of noninvasive carbohydrate breath tests, which have a sensitivity of only approximately 60 percent [<a href="#rid20">20</a>]. Jejunal aspirate cultures are considered the reference standard, although they are difficult to perform. (See  <a class="medical medical_review" href="/z/d/html/4776.html" rel="external">"Small intestinal bacterial overgrowth: Clinical manifestations and diagnosis"</a>.)</p><p>Treatment consists of an antibiotic course, which will cure the diarrhea. (See  <a class="medical medical_review" href="/z/d/html/4778.html" rel="external">"Small intestinal bacterial overgrowth: Management"</a>.)</p><p class="headingAnchor" id="H238225907"><span class="h3">Fat malabsorption due to other causes</span><span class="headingEndMark"> — </span>Fat malabsorption occurs for reasons other than SIBO in patients undergoing treatment for cancer. Pancreatic exocrine insufficiency is reported in the setting of conditioning regimens preceding hematopoietic cell transplantation [<a href="#rid21">21</a>] and following pancreaticoduodenectomy. (See  <a class="medical medical_review" href="/z/d/html/91408.html" rel="external">"Surgical resection of lesions of the head of the pancreas", section on 'Pancreatic enzyme supplementation'</a>.)</p><p>Obstruction of lymphatic vessels secondary to tumor infiltration, radiation therapy-induced intestinal lymphangiectasia, and multiple small bowel resections (&gt;100 cm of small bowel resected) may also result in malabsorption of free fatty acids, leading to diarrhea [<a href="#rid15">15</a>].</p><p>Bile acid malabsorption or bile acid diarrhea (excessive secretion of bile acids) may result from chemotherapy-induced epithelial damage of the terminal ileum. Among 506 patients with a history of prior cancer treatment including radiation, surgery, or chemotherapy who were evaluated in a gastroenterology clinic at the Royal Marsden Hospital because of chronic loose or watery stool, bile acid malabsorption or bile acid diarrhea was newly diagnosed in over 40 percent [<a href="#rid22">22</a>]. Patients who had pelvic chemoradiation were more likely to have bile acid malabsorption than those who had pelvic radiation alone, possibly due to radiation sensitization of the terminal ileum. Right hemicolectomy was associated with bile acid malabsorption due to resection of the terminal ileum. Bile acid malabsorption/bile acid diarrhea was also frequently associated with pancreatoduodenectomy.</p><p>A referral to gastroenterology should be considered for patients with CRD that persists throughout the chemotherapy cycle (eg, those with chronic loose stool) to evaluate the possibility of bile acid malabsorption. An empiric trial of a bile-acid binding resin (eg, <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">cholestyramine</a>) is another option. (See  <a class="medical medical_review" href="/z/d/html/2591.html" rel="external">"Approach to the adult with chronic diarrhea in resource-abundant settings"</a>.)</p><p class="headingAnchor" id="H1225714604"><span class="h3">Infectious causes</span><span class="headingEndMark"> — </span>Among the infectious agents that may cause acute diarrhea in adults are <em>Salmonella</em> species, <em>Shigella</em> species, <em>Campylobacter</em>, <em>Escherichia coli</em>, and <em>C. difficile</em>. A routine stool culture will identify <em>Salmonella</em>, <em>Campylobacter</em>, and <em>Shigella</em>, the three most common causes of bacterial diarrhea in the United States. A stool culture that is positive for one of these pathogens in a patient with acute diarrheal symptoms can be interpreted as a true positive.</p><p class="headingAnchor" id="H3582383389"><span class="h4">Clostridioides difficile-associated colitis</span><span class="headingEndMark"> — </span><em>Clostridioides</em> <em>difficile</em> colitis is a common problem in patients with cancer, mostly due to the high rate of oral antibiotic use and hospitalization. However, several reports have described this complication in patients without any prior antibiotic use following chemotherapy [<a href="#rid23">23-25</a>]. The proposed mechanism is chemotherapy-induced intestinal damage that facilitates the proliferation of <em>C. difficile</em>.</p><p>A frequent occurrence of <em>C. difficile</em>-related diarrheal episodes has been reported in patients treated with paclitaxel-containing regimens, especially with the use of "dose-dense" regimens [<a href="#rid26">26</a>]. The spectrum of illness varies from mild to fulminant; management is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2699.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/2698.html" rel="external">"<i>Clostridioides difficile</i> infection in adults: Treatment and prevention"</a>.)</p><p class="headingAnchor" id="H2591960355"><span class="h4">Bloody diarrhea</span><span class="headingEndMark"> — </span>For patients with bloody diarrhea, two potential pathogens, enterohemorrhagic <em>E.</em> <em>coli</em> (<em>E. coli</em> O157:H7 [EHEC]) and <em>Entamoeba</em>, warrant additional testing. EHEC can be isolated on special plates, or identified with antigen testing or polymerase chain reaction of stool. In addition to culture, we check bloody stools for Shiga toxin, and fecal leukocytes or lactoferrin, if available; if the fecal leukocyte/lactoferrin test is negative, we test for amebiasis.</p><p class="headingAnchor" id="H1096062318"><span class="h3">Neutropenic enterocolitis</span><span class="headingEndMark"> — </span>Neutropenic enterocolitis (a form of necrotizing enterocolitis or typhlitis) is one of the most common gastrointestinal complications in leukemic patients who are undergoing induction therapy, and can occur in other malignancies and following stem cell-supported high-dose chemotherapy [<a href="#rid27">27,28</a>].</p><p>The pathogenesis, risk factors, diagnosis, and management of patients with neutropenic enterocolitis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2690.html" rel="external">"Neutropenic enterocolitis (typhlitis)"</a>.)</p><p class="headingAnchor" id="H1885516241"><span class="h3">Ischemic colitis</span><span class="headingEndMark"> — </span>A small number of cases of ischemic colitis have been reported with docetaxel-containing regimens in patients with metastatic breast cancer, including 3 of 14 patients in a phase I study of <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> and <a class="drug drug_general" data-topicid="10046" href="/z/d/drug information/10046.html" rel="external">vinorelbine</a> [<a href="#rid29">29,30</a>]. The typical onset is 4 to 10 days following administration. Patients with acute colonic ischemia usually present with rapid onset of mild abdominal pain and tenderness over the affected bowel, commonly on the left side of the abdomen. Mild to moderate amounts of rectal bleeding or bloody diarrhea typically develop within 24 hours of the onset of abdominal pain. (See  <a class="medical medical_review" href="/z/d/html/2559.html" rel="external">"Overview of intestinal ischemia in adults"</a>.)</p><p class="headingAnchor" id="H502938557"><span class="h3">Stool impaction</span><span class="headingEndMark"> — </span>Patients who have anorexia, abdominal bloating or pain, and frequent soft or loose stool, as opposed to watery diarrhea, may have overflow diarrhea (ie, passage of stool around an impaction) [<a href="#rid15">15</a>]. A digital rectal examination will usually discover the impaction.</p><p class="headingAnchor" id="H1492527827"><span class="h3">Lymphocytic colitis</span><span class="headingEndMark"> — </span>Patients receiving treatment with <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a> may develop lymphocytic colitis (microscopic colitis), for which specific treatment with <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a> may be beneficial [<a href="#rid31">31</a>]. These cases will typically present with diarrhea that persists throughout the entire chemotherapy cycle (ie, chronic rather than acute diarrhea). Patients with chronic diarrhea during chemotherapy should be referred to gastroenterology for a workup to include colonoscopy. (See  <a class="medical medical_review" href="/z/d/html/4071.html" rel="external">"Microscopic (lymphocytic and collagenous) colitis: Clinical manifestations, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H1242912147"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Treatment for CRD includes nonpharmacologic and pharmacologic interventions to slow the diarrhea, and careful serial evaluation to assess response to therapy and to rule out significant volume depletion or other risk factors that would require targeted intervention or hospitalization.</p><p class="headingAnchor" id="H3312347173"><span class="h2">Management according to the severity of diarrhea and other exacerbating factors</span><span class="headingEndMark"> — </span>Initial management depends on the severity of diarrhea and whether or not additional "risk factors" are present. In keeping with consensus-based guidelines from an academic panel convened to address management of CRD in 2004 [<a href="#rid13">13</a>], we recommend classifying patients with CRD as "uncomplicated" or "complicated." An algorithmic approach to evaluation and management of CRD according to severity and exacerbating factors is provided  (<a class="graphic graphic_algorithm graphicRef64251" href="/z/d/graphic/64251.html" rel="external">algorithm 1</a>), and the specific treatment strategies are discussed in more detail in the sections below.</p><p class="headingAnchor" id="H3305114236"><span class="h3">Uncomplicated, mild to moderate chemotherapy-related diarrhea</span><span class="headingEndMark"> — </span>Patients with mild to moderate (grade 1 or 2  (<a class="graphic graphic_table graphicRef65649" href="/z/d/graphic/65649.html" rel="external">table 1</a>)) diarrhea and no moderate to severe abdominal cramping, grade 2 or worse nausea/vomiting  (<a class="graphic graphic_table graphicRef69015" href="/z/d/graphic/69015.html" rel="external">table 3</a>), decreased performance status, fever, frank bleeding, or suspected dehydration are classified as "uncomplicated." These patients can initially be managed conservatively at home with oral hydration, dietary modification, and antidiarrheal therapy (typically <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> 4 mg to start, and then 2 mg every four hours or after each loose stool). (See <a class="local">'General measures'</a> below and <a class="local">'Loperamide and diphenoxylate-atropine'</a> below.)</p><p>If symptoms persist after 12 to 24 hours (but are not worse or associated with worrisome signs and/or symptoms), the <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> dose can be increased to 2 mg every two hours. If mild to moderate diarrhea persists 12 to 24 hours later despite the higher dose of loperamide, patients should be evaluated in the office; be assessed for hydration status, neutropenia, and electrolyte abnormalities; and have stool sent for culture and diagnostic testing for toxin-producing strains of <em>C. difficile</em>. In the absence of an added risk factor for complicated diarrhea (moderate to severe abdominal cramping, grade 2 or worse nausea/vomiting  (<a class="graphic graphic_table graphicRef69015" href="/z/d/graphic/69015.html" rel="external">table 3</a>), decreased performance status, fever, hypotension, neutropenia, frank bleeding), chest pain, or prior admission for CRD, outpatient <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> is a reasonable next step. (See <a class="local">'Patients refractory to loperamide'</a> below.)</p><p>Persistent mild to moderate diarrhea despite the higher dose of <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> and the addition of <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a>, any progression to severe (grade 3 or 4  (<a class="graphic graphic_table graphicRef65649" href="/z/d/graphic/65649.html" rel="external">table 1</a>)) diarrhea, or the development of an added risk factor for complicated diarrhea should prompt admission to the hospital and further evaluation and treatment.</p><p class="headingAnchor" id="H612094018"><span class="h3">Complicated chemotherapy-related diarrhea</span><span class="headingEndMark"> — </span>Patients who present with grade 3 or 4 diarrhea  (<a class="graphic graphic_table graphicRef65649" href="/z/d/graphic/65649.html" rel="external">table 1</a>) and those with grade 1 or 2 diarrhea associated with moderate to severe abdominal cramping, grade 2 or worse nausea/vomiting  (<a class="graphic graphic_table graphicRef69015" href="/z/d/graphic/69015.html" rel="external">table 3</a>), declining performance status, fever, sepsis, neutropenia, frank bleeding, or dehydration are classified as "complicated." Year 2014 guidelines for CRD from a multidisciplinary British group include recognition of these complicating symptoms, but they also include chest pain and a previous admission for CRD as signs of potentially severe diarrhea necessitating aggressive management [<a href="#rid15">15</a>].</p><p>Most of these patients warrant admission for intravenous fluids, <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a>, monitoring of cardiovascular status, serial assessment of electrolytes, and antibiotics, if needed. However, selected patients who have grade 3 diarrhea that has not yet been treated adequately with <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a>, who are well hydrated, and who have no worrisome signs or symptoms may be managed at home initially [<a href="#rid15">15</a>]. (See <a class="local">'Loperamide and diphenoxylate-atropine'</a> below.)</p><p>If not already done, cultures of stool and diagnostic testing for toxin-producing strains of <em>C. difficile</em> should be performed. For patients with bloody diarrhea, at least two potential pathogens, enterohemorrhagic <em>E. coli</em> (EHEC) and <em>Entamoeba histolytica</em>, warrant additional testing. In addition to culture, bloody stools should be checked for Shiga toxin, and fecal leukocytes or lactoferrin, if available; if the fecal leukocyte/lactoferrin test is negative, we test for intestinal amebiasis. (See  <a class="medical medical_review" href="/z/d/html/2717.html" rel="external">"Approach to the adult with acute diarrhea in resource-abundant settings", section on 'Bloody diarrhea'</a> and  <a class="medical medical_review" href="/z/d/html/5727.html" rel="external">"Intestinal Entamoeba histolytica amebiasis", section on 'Diagnosis'</a>.)</p><p>Patients with fever, peritoneal signs, or bloody diarrhea should have an urgent CT scan of the abdomen and pelvis, and a surgical consultation [<a href="#rid15">15</a>]. If the patient is neutropenic, avoidance of surgery is prudent, if possible. (See <a class="local">'Investigations'</a> above.)</p><p>Blood cultures are recommended for neutropenic patients with CRD or for those with fever or bloody diarrhea.</p><p>For patients who develop severe symptoms (diarrhea, mucositis, myelosuppression) during a first chemotherapy cycle containing a fluoropyrimidine, in whom deficiency of one of the fluoropyrimidine metabolizing enzymes (ie, dihydropyrimidine dehydrogenase [DPD] or thymidylate synthetase) is suspected, or who have had an unintentional overdose of <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> [FU] or <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a>, the need for <a class="drug drug_general" data-topicid="9537" href="/z/d/drug information/9537.html" rel="external">uridine triacetate</a> should be addressed. In order to be effective, uridine triacetate must be started within 96 hours of the last exposure. (See <a class="local">'Uridine triacetate'</a> below.)</p><p class="headingAnchor" id="H54977943"><span class="h2">General measures</span><span class="headingEndMark"> — </span>Initial nonpharmacologic measures include avoidance of foods that might aggravate the diarrhea  (<a class="graphic graphic_table graphicRef57475" href="/z/d/graphic/57475.html" rel="external">table 2</a>) and aggressive oral rehydration with fluids that contain water, salt, and sugar (since glucose promotes intestinal sodium absorption), such as broth or Gatorade [<a href="#rid32">32</a>]. These principles are similar to those used for initial treatment of infectious diarrhea. (See  <a class="medical medical_review" href="/z/d/html/2717.html" rel="external">"Approach to the adult with acute diarrhea in resource-abundant settings", section on 'Fluid repletion'</a> and  <a class="medical medical_review" href="/z/d/html/2717.html" rel="external">"Approach to the adult with acute diarrhea in resource-abundant settings", section on 'Dietary guidance'</a>.)</p><p>Because of potential mucosal damage and loss of absorptive surfaces, patients should ingest easy-to-digest food until the CRD resolves. Patients should be advised to follow a "BRAT" diet (ie, bananas, rice, applesauce, and toast) [<a href="#rid16">16</a>]. Fresh fruits and vegetables should be avoided, as they will worsen diarrhea, except for bananas, which can be binding. High-osmolar dietary supplements should be avoided [<a href="#rid13">13</a>]. Patients with CRD may be temporarily lactose intolerant [<a href="#rid6">6,7</a>] and should, thus, follow a lactose-free diet  (<a class="graphic graphic_table graphicRef54826" href="/z/d/graphic/54826.html" rel="external">table 4</a>) until the CRD resolves. Particularly if diarrhea is severe, a clear liquid diet can provide bowel rest and may decrease the volume of diarrhea.</p><p>Alcohol should be avoided, as it is dehydrating. Caffeine should be avoided, as it stimulates gastrointestinal (GI) tract motility.</p><p>Patients should be instructed to stop other medications and supplements that could cause diarrhea, such as stool softeners, laxatives, milk thistle, aloe, saw palmetto, Siberian ginseng, plantago seeds, coenzyme Q10, high doses of <a class="drug drug_general" data-topicid="9776" href="/z/d/drug information/9776.html" rel="external">vitamin C</a>, and green tea [<a href="#rid16">16</a>]. Lactose is often used as an excipient in pharmaceutical drugs. For most drugs, the amount of lactose is insufficient to induce symptoms in persons with lactose intolerance, although highly sensitive individuals may be affected, especially if they ingest multiple medications that contain lactose [<a href="#rid33">33,34</a>].</p><p class="headingAnchor" id="H44193641"><span class="h2">Withholding chemotherapy</span><span class="headingEndMark"> — </span>The management of oral antineoplastic therapy in patients who develop diarrhea varies according to the specific drug, and the United States prescribing information generally includes recommendations for dose modification for individual drugs. In general:</p><p class="bulletIndent1"><span class="glyph">●</span>Anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs; <a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">afatinib</a>, <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">erlotinib</a>, <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">gefitinib</a>) – For grade 2 diarrhea, continue the drug. If the patient does not respond to <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> by 48 hours, temporarily discontinue the drug until diarrhea returns to grade 1, after which the drug can be resumed with a dose reduction (afatinib and erlotinib). For grade 3 or 4 diarrhea, withhold the TKI until diarrhea reaches grade 1, then resume, usually with a dose reduction. If the diarrhea does not resolve to grade 1 within 14 days, the drug should be permanently discontinued.</p><p></p><p class="bulletIndent1">For <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D63319b01-cad6-4d0a-c39b-938fa951a808&amp;token=n1PBkuOvZqiUmJHawz%2Fdda1i7OP%2FTa5Opch6k9lE68H6cY8a3Pypk82sPqEjdJOXJ9Y6ABpmEl1Uu%2B4%2BtOS6mQW8%2FhznQRzaEYqviZH%2BwKRlzC3ajPmeAbNJwmDlWcXr&amp;TOPIC_ID=98342" target="_blank">lapatinib</a>, the United States prescribing information recommends that the drug be interrupted in patients with grade 3 diarrhea, or grade 1 or 2 diarrhea with complicating features (moderate to severe abdominal cramping, grade 2 or worse nausea/vomiting  (<a class="graphic graphic_table graphicRef69015" href="/z/d/graphic/69015.html" rel="external">table 3</a>), decreased performance status, fever, sepsis, neutropenia, frank bleeding, or dehydration), and resumed with a dose reduction after recovery to grade 1. Discontinue the drug permanently for grade 4 diarrhea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For the anaplastic lymphoma kinase (ALK) inhibitor <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Dfff5d805-4ffd-4e8e-8e63-6f129697563e&amp;token=ATdyz92HVOXScDDg%2FVN78eBdfLAaeDeWnCTCI9ftR6IOCRyJg2nzKM99kfJwJRKyS%2Bukykgdkr5%2BkVj2vZ7AI%2FPRfIp6vhhw%2FO7UTaiUViwYUHeO%2BZwFqWSQvcEpeVRX&amp;TOPIC_ID=98342" target="_blank">ceritinib</a>, the United States prescribing information recommends withholding the drug for severe or intolerable diarrhea, despite optimal antidiarrheal therapy, and resuming once resolved with a dose reduction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The United States prescribing information for <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D8345d55e-ad02-4726-a04b-1a46e3337a4b&amp;token=2Ae773rvsmSNZWoIw48MPkgU8yAimrMBWd5f83FOOSfpeTKqVZYnTXMdqhGYbeLScsjid5wcktjtilYXTCOsjtbmyL6d8vGPfyf793kjW%2BWnjEP%2By1hw4sg4duqrS7ID&amp;TOPIC_ID=98342" target="_blank">capecitabine</a> recommends that the drug be temporarily interrupted for grade 2 or worse diarrhea until resolved to grade 0 or 1. </p><p></p><p>While the United States prescribing information does not explicitly make this statement, we also discontinue infusional FU for grade 2 or worse diarrhea until resolved to grade 0 or 1.</p><p class="headingAnchor" id="H1437799104"><span class="h2">Pharmacologic management</span></p><p class="headingAnchor" id="H3955116130"><span class="h3">Loperamide and diphenoxylate-atropine</span><span class="headingEndMark"> — </span>We recommend <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> rather than <a class="drug drug_general" data-topicid="9370" href="/z/d/drug information/9370.html" rel="external">diphenoxylate-atropine</a> for initial therapy of CRD. For mild to moderate (grade 1 or 2) uncomplicated CRD, we suggest an initial dose of 4 mg, followed by 2 mg every four hours or 2 mg after each loose stool (maximum daily dose 16 mg per day). For patients with severe (grade 3 or 4) diarrhea; mild to moderate diarrhea that is complicated by moderate to severe abdominal cramping, grade 2 or worse nausea/vomiting  (<a class="graphic graphic_table graphicRef69015" href="/z/d/graphic/69015.html" rel="external">table 3</a>), decreased performance status, fever, sepsis, neutropenia, frank bleeding, or dehydration; or mild to moderate uncomplicated diarrhea that persists after 24 hours of loperamide, we suggest high-dose loperamide (4 mg initially, followed by 2 mg every two hours; maximum daily dose 16 mg).</p><p>The mainstays of pharmacologic therapy for CRD are opioids. <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">Loperamide</a> (Imodium) and <a class="drug drug_general" data-topicid="9370" href="/z/d/drug information/9370.html" rel="external">diphenoxylate-atropine</a> (Lomotil) are the most commonly used, and both are US Food and Drug Administration (FDA)-approved for this indication. Both have a rapid onset of action.</p><p><a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">Loperamide</a> is a synthetic opioid that binds to mu opiate receptors in the intestinal wall and inhibits peristalsis by inhibiting the release of acetylcholine through activation of the mu opioid receptors [<a href="#rid35">35</a>]. This slows GI transit time, allowing more time for absorption of water in the intestine [<a href="#rid36">36-38</a>]. Inhibition of acetylcholine release also leads to antisecretory activity because muscarinic acetylcholine receptors exist on secretory epithelial cells in the intestinal wall [<a href="#rid39">39</a>]. As a result of all of these actions, loperamide reduces fluid and electrolyte loss, decreases fecal volume, and increases stool consistency.</p><p><a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">Loperamide</a> is rapidly absorbed from the GI tract and extensively metabolized by the liver. The amount of loperamide entering the systemic circulation is minimal (systemic bioavailability is only 0.3 percent), and the blood brain barrier prevents any absorbed loperamide from entering the central nervous system [<a href="#rid15">15</a>]. As such, it has a much wider margin between central and peripheral opioid action than do other centrally acting opioids, such as <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a>, and even diphenoxylate [<a href="#rid36">36</a>]. The main adverse effect is constipation.</p><p>Diphenoxylate is a synthetic opioid chemically related to <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">meperidine</a>; it inhibits excessive GI motility and GI propulsion; commercial preparations contain a subtherapeutic amount of <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> to discourage abuse. Excess doses of <a class="drug drug_general" data-topicid="9370" href="/z/d/drug information/9370.html" rel="external">diphenoxylate-atropine</a> can result in symptoms of excess cholinergic and central narcotic effects, including drowsiness, flushing, dry mouth, tachycardia, dilated pupils, rash, and nausea [<a href="#rid40">40</a>]. </p><p>Both <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> and <a class="drug drug_general" data-topicid="9370" href="/z/d/drug information/9370.html" rel="external">diphenoxylate-atropine</a> are effective at controlling acute and chronic diarrhea of various causes. There are no randomized trials directly comparing loperamide with diphenoxylate in patients with CRD. However, efficacy data from double-blind crossover studies comparing these agents in a variety of settings of non-chemotherapy-related acute and chronic diarrhea suggest that loperamide is the more effective agent, providing more rapid control of diarrhea and prolonging the time to first recurrence of diarrhea [<a href="#rid41">41-48</a>]; furthermore, it has a more favorable side effect profile, especially lacking central narcotic activity [<a href="#rid49">49</a>]. Loperamide is the preferred approach in several published guidelines for treatment of CRD [<a href="#rid13">13,15,50,51</a>].</p><p>The standard dose of <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> for CRD is an initial 4 mg dose, followed by 2 mg every four hours or after every loose stool, maximum 16 mg daily. Four randomized placebo-controlled trials established the efficacy of this dose of loperamide in a variety of settings of both acute and chronic diarrhea [<a href="#rid52">52-55</a>]. This dose has been used empirically for patients with CRD and has been shown to be effective [<a href="#rid56">56-59</a>]. However, this regimen is only moderately effective for severe (grade 3 or 4) CRD [<a href="#rid59">59,60</a>]. In one study among patients with grade 1 to 4 diarrhea due to FU-based chemotherapy, loperamide at 4 mg for the first dose, followed by 4 mg every eight hours (16 mg per 24 hours) for up to 48 hours, led to resolution of grade 1 or 2 diarrhea in 84 percent of patients but was effective in only 52 percent of patients with grade 3 or 4 diarrhea  (<a class="graphic graphic_table graphicRef65649" href="/z/d/graphic/65649.html" rel="external">table 1</a>) [<a href="#rid59">59</a>].</p><p>More aggressive regimens may be recommended for severe or complicated diarrhea (eg, 4 mg initially, then 2 mg every two hours or 4 mg every four hours until diarrhea free for 12 hours). However, doses higher than 16 mg daily should be avoided due to the risk of cardiac arrhythmias [<a href="#rid61">61-63</a>].</p><p class="headingAnchor" id="H1992129762"><span class="h3">Octreotide</span><span class="headingEndMark"> — </span>We recommend initiating <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> for any patient with CRD that is refractory to <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a>. We suggest initiating therapy at 100 or 150 mcg subcutaneously three times daily (or 50 to 150 mcg/hour intravenously). The octreotide dose should be rapidly escalated to 500 mcg subcutaneously/intravenously three times a day if lower doses are not effective.</p><p><a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">Octreotide</a>, a synthetic somatostatin analog, is effective for the control of diarrhea associated with a number of conditions, including carcinoid syndrome, vasoactive intestinal polypeptide (VIP)- and gastrin-secreting tumors, and short bowel syndrome. (See  <a class="medical medical_review" href="/z/d/html/16638.html" rel="external">"Treatment of the carcinoid syndrome", section on 'Somatostatin-analog therapy'</a> and  <a class="medical medical_review" href="/z/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management", section on 'Somatostatin analogs'</a> and  <a class="medical medical_review" href="/z/d/html/2584.html" rel="external">"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)", section on 'Somatostatin analogs'</a> and  <a class="medical medical_review" href="/z/d/html/4773.html" rel="external">"Management of short bowel syndrome in adults", section on 'Pharmacologic therapy to reduce fluid loss'</a>.)</p><p><a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">Octreotide</a> diminishes diarrhea via several mechanisms. It acts directly on epithelial cells to reduce the secretion of a number of pancreatic and GI hormones, such as VIP, serotonin, gastrin, <a class="drug drug_general" data-topicid="10259" href="/z/d/drug information/10259.html" rel="external">secretin</a>, and pancreatic polypeptide [<a href="#rid64">64</a>]. In both animal models and clinical studies, it prolongs intestinal transit time, promotes intestinal absorption, and decreases secretion of fluids and electrolytes [<a href="#rid65">65-67</a>]. Absorption after subcutaneous injection is rapid and complete, but the duration of effect is 6 to 12 hours, necessitating multiple daily doses or infusional intravenous therapy [<a href="#rid56">56</a>]. A long-acting depot suspension that is released slowly is available for intramuscular use (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Dd0b7fe9e-7000-4b79-ba3b-291ce92c14f9&amp;token=DdJp27S16YHiL5g0p1Ndp7MhhaJ0U86GVYvPFVOJdfefztpPdL77Dz1BTYCUyo0VblXFvF%2F0qt4ZRD4eWwMsadqciv64H3cLbeesAwjdkOYQUoc6mq3Ck43grekHqXjx&amp;TOPIC_ID=98342" target="_blank">Sandostatin long-acting release [LAR]</a>); it is designed to be injected every four weeks. Peak serum levels after intramuscular injection occur after one hour, they slowly decline over three to five days, then slowly increase again and reach a plateau over two to three weeks. Octreotide is approved by the FDA for the treatment of diarrhea related to VIP-secreting tumors and symptoms due to carcinoid syndrome. (See  <a class="medical medical_review" href="/z/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H3665408015"><span class="h4">Patients refractory to loperamide</span><span class="headingEndMark"> — </span>We recommend that patients who have persistent diarrhea despite 24 to 48 hours of <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> use be treated with <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> [<a href="#rid13">13</a>]. It is unlikely that higher doses of loperamide will be beneficial [<a href="#rid13">13</a>]. There are no published data on the use of <a class="drug drug_general" data-topicid="9370" href="/z/d/drug information/9370.html" rel="external">diphenoxylate-atropine</a> in the setting of diarrhea refractory to loperamide, but as diphenoxylate-atropine is another opioid, it is unlikely that it will be effective for patients with severe diarrhea despite aggressive loperamide use. We suggest an initial octreotide dose of 100 to 150 mcg subcutaneously three times daily, with escalation to 500 mcg three times daily and, rarely, higher (up to 2000 mcg three times daily), as needed for refractory cases.</p><p>Benefit from <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> has been shown in patients with CRD from fluoropyrimidines, <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>, and FU-based chemoradiotherapy who are failing to respond to <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> or <a class="drug drug_general" data-topicid="9370" href="/z/d/drug information/9370.html" rel="external">diphenoxylate-atropine</a> [<a href="#rid56">56,57,68-71</a>]. In one trial of 32 patients with grade 2 or 3 CRD (from a variety of agents, including FU, irinotecan, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>) who were refractory to loperamide and treated with octreotide (100 mcg three times daily for three days, then 50 mcg three times daily for three days), complete resolution of diarrhea was obtained in 30 (94 percent) [<a href="#rid71">71</a>]. Resolution occurred within 24 hours in five, within 48 hours in 14, and within 72 hours in 11. Nineteen patients were successfully treated as outpatients. No adverse effects related to octreotide were observed in this trial, although others report local pain at the injection site, flatulence, nausea, fatigue, weakness, and constipation [<a href="#rid72">72</a>].</p><p>The optimal dose has not been established. Most guidelines suggest initiating therapy with 100 or 150 mcg three times daily based on efficacy as demonstrated in the studies cited above [<a href="#rid13">13,15,50,51,73</a>].</p><p>However, at least some data suggest that a dose-response relationship with escalating doses provides better control of diarrhea [<a href="#rid56">56,68,70,74</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>The safety of <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> at subcutaneous doses of 50 to 2500 mcg three times daily for five days was evaluated in a dose-escalation study conducted in patients with grade 2 or worse diarrhea associated with FU therapy [<a href="#rid68">68</a>]. The maximally tolerated dose was 2000 mcg three times daily. There was a significant correlation between dose and complete resolution of diarrhea, and a significantly greater chance of completing therapy as the dose of octreotide increased.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The only prospective comparison of <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> 100 and 500 mcg, both administered subcutaneously three times a day in 59 patients with grade 3 or 4 diarrhea due to FU, found complete resolution of diarrhea within five days in a significantly higher percentage of patients treated initially at the higher dose (90 versus 61 percent) [<a href="#rid74">74</a>].</p><p></p><p>These data support upward titration of the <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> dose up to 2000 mcg three times daily. The side effects of octreotide are generally mild, including bloating, cramping, flatulence, and fat malabsorption. Hypersensitivity-like reactions and hypoglycemia can occur at higher doses (2500 mcg three times daily) [<a href="#rid68">68</a>]. Octreotide should be discontinued when diarrhea has resolved to prevent ileus from developing [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H2114014216"><span class="h4">Versus loperamide as initial therapy</span><span class="headingEndMark"> — </span>At least two randomized trials in patients with CRD showed that <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> was more effective than standard-dose <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> for initial treatment of grade 2 or 3 diarrhea (90 versus 15 percent resolution of diarrhea by day 3 in one trial [<a href="#rid60">60</a>] and 80 versus 30 percent resolution by day four in the second [<a href="#rid75">75</a>]). However, loperamide dosing was relatively low by modern standards in both trials (4 mg initially, then 2 mg every six hours in one [<a href="#rid60">60</a>] and 4 mg three times daily in the second [<a href="#rid75">75</a>]). Given the high cost of octreotide and the general effectiveness of loperamide when administered at therapeutic doses, octreotide is generally reserved as a second-line therapy for patients who do not respond to high-dose loperamide. (See <a class="local">'Loperamide and diphenoxylate-atropine'</a> above.)</p><p class="headingAnchor" id="H3590486316"><span class="h4">Octreotide long-acting release</span><span class="headingEndMark"> — </span>Subcutaneous <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> effectively relieves CRD but requires three-times-daily injections. As noted above, octreotide is available as a depot formulation for intramuscular use. One small case series of 11 patients failing conventional antidiarrhea therapy (<a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> and <a class="drug drug_general" data-topicid="9370" href="/z/d/drug information/9370.html" rel="external">diphenoxylate-atropine</a>) suggests efficacy at resolving severe (grade 3 or 4) CRD for a single dose of octreotide LAR (starting dose 30 mg) [<a href="#rid76">76</a>]. Only one of four patients receiving a 20 mg dose had resolution of diarrhea, while the remaining three and all of those initially treated with a 30 mg initial dose had resolution of diarrhea [<a href="#rid77">77,78</a>].</p><p>Given that subcutaneous <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> dosing for outpatients is inconvenient, and many patients will not be able to administer the injections or have insurance coverage for outpatient injections, administration of a single dose of octreotide LAR (30 mg) may be a reasonable option for patients with loperamide-refractory CRD who are being managed as outpatients. However, a study of octreotide LAR as secondary prophylaxis of CRD found that when the next cycle of chemotherapy was administered at a 25 percent lower dose and was given with octreotide LAR 30 mg, 8 of 29 patients developed grade 2 or worse diarrhea in that cycle. The authors hypothesized that the pharmacokinetic profile of octreotide LAR, which results in lower drug concentrations for the first 10 days after injection, may have contributed to the lack of efficacy.</p><p class="headingAnchor" id="H1222947861"><span class="h3">Other antidiarrheal agents</span><span class="headingEndMark"> — </span>Other antidiarrheal agents have been evaluated in patients with CRD.</p><p class="bulletIndent1"><span class="glyph">●</span>Anticholinergic drugs are not commonly used because of side effects. However, they can be helpful when diarrhea is associated with significant cramping.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Deodorized <a class="drug drug_general" data-topicid="9721" href="/z/d/drug information/9721.html" rel="external">tincture of opium</a> (DTO) is a widely used antidiarrheal agent, despite the absence of literature reports supporting efficacy for treatment of chemotherapy-induced diarrhea. DTO contains the equivalent of 10 mg/mL <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>. The recommended dose is 10 to 15 drops in water every three to four hours [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1">Outside of the United States, an alternative is <a class="drug drug_general" data-topicid="9740" href="/z/d/drug information/9740.html" rel="external">paregoric</a>, camphorated tincture of opium, a less concentrated preparation that contains the equivalent of 0.4 mg/mL <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a>. The recommended dose is 5 mL (one teaspoonful) in water every three to four hours. This preparation has been discontinued in the United States.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Racecadotril is an enkephalinase inhibitor that blocks epithelial cyclic adenosine monophosphate (AMP)-mediated secretion. It has moderate activity in patients with irinotecan-induced diarrhea [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">Budesonide</a> is an orally administered, topically active synthetic steroid with low systemic activity due to extensive first-pass metabolism in the liver. It has proven efficacy in patients suffering from diarrhea caused by inflammatory bowel disease and collagenous colitis. At least one report suggests possible efficacy for oral budesonide in patients with diarrhea caused by <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> or FU [<a href="#rid80">80</a>]. In a phase I study involving 14 patients with loperamide-refractory grade 3 or 4 diarrhea, severity was reduced by at least two grades in 86 percent of the irinotecan-treated patients and 57 percent of those receiving FU.</p><p></p><p class="bulletIndent1">One setting in which <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a> may be beneficial is in patients receiving <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a>, which has been associated with microscopic (lymphocytic) colitis [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/4071.html" rel="external">"Microscopic (lymphocytic and collagenous) colitis: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="headingAnchor" id="H665597128"><span class="h3">Oral antibiotics</span><span class="headingEndMark"> — </span>There is no consensus on the appropriate role for oral antibiotics in patients with CRD. The 2004 guidelines from Benson and colleagues recommend starting oral antibiotics for mild to moderate, uncomplicated diarrhea that persisted after 12 to 24 hours of initial <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> therapy; these guidelines were published around the time that deaths were reported in patients with CRD from <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> in conjunction with bolus FU and <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> (the IFL regimen), many of which occurred in the setting of neutropenia. As noted above, this regimen has fallen out of favor. More recent British guidelines do not include this recommendation [<a href="#rid15">15</a>]. We would start antibiotics only for patients with fever, hypotension, peritoneal signs, neutropenia, or bloody diarrhea and would use intravenous antibiotics in these settings.</p><p class="headingAnchor" id="H4142975986"><span class="h3">Uridine triacetate</span><span class="headingEndMark"> — </span>For patients who have received a fluoropyrimidine, who develop severe diarrhea after the initial dose, in conjunction with severe myelosuppression, mucositis, cardiotoxicity, or neurotoxicity, or after an unintentional overdose, and who are identified within 96 hours of the last chemotherapy dose, we recommend <a class="drug drug_general" data-topicid="9537" href="/z/d/drug information/9537.html" rel="external">uridine triacetate</a>. For individuals with ongoing severe fluoropyrimidine-related toxicity (diarrhea, myelosuppression, mucositis, cardiotoxicity, or neurotoxicity) who are identified later than 96 hours after the last chemotherapy dose, we also suggest initiation of uridine triacetate. Following recovery of unusually severe toxicity after the first dose of a fluoropyrimidine, testing for specific high-risk mutations/polymorphisms in FU-metabolizing enzymes should be undertaken prior to retreatment with a fluoropyrimidine. (See <a class="local">'Pharmacogenetic and pharmacokinetic testing'</a> below.)</p><p><a class="drug drug_general" data-topicid="9537" href="/z/d/drug information/9537.html" rel="external">Uridine triacetate</a> (originally called vistonuridine) is an orally administered prodrug of uridine, a specific pharmacologic antidote to fluoropyrimidines, including FU and <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a>. It is a safe, effective, and potentially life-saving treatment for overdoses of these agents. Uridine triacetate was studied in 173 adult and pediatric patients who were treated in two separate trials and had either received an overdose of FU or capecitabine (n = 147) or had early onset, unusually severe, or rapid-onset life-threatening toxicities within 96 hours after receiving FU (n = 26, the fraction who had DPD deficiency as the cause for severe early toxicity could not be determined) [<a href="#rid81">81</a>]. Overall, 137 of 142 assessable overdose patients (five were lost to follow-up) treated with uridine triacetate (96 percent) survived to 30 days, had rapid reversal of acute neurotoxicity or cardiotoxicity (affecting 12 patients), and had either prevention of or recovery from severe mucositis or leucopenia. Of the 141 uridine triacetate patients with a diagnosis of cancer, 53 were able to resume chemotherapy within 30 days. Among the 26 patients treated for early onset toxicity following fluoropyrimidine therapy, 21 survived to 30 days (81 percent); all five deaths were in patients who initiated uridine triacetate beyond 96 hours after the last dose of the fluoropyrimidine. These results compared favorably with a historical cohort of 25 patients, derived from published case reports, who had experienced FU overdose and for whom the report contained information about the total dose of FU administered, the time and rate of administration, and the patient outcomes. Overall, 21 died (84 percent). Adverse events attributable to uridine triacetate were mild and infrequent, and included diarrhea, nausea, and vomiting.</p><p>The dismal outcome for supportive care alone in these patients is underscored by an analysis of FU toxicity cases from the FDA Adverse Event Reporting System (FAERS) [<a href="#rid82">82</a>]. Of the reports of fatalities in patients who experienced early onset, severe, or life-threatening toxicity after FU (n = 58) or <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> (n = 145) despite intensive supportive care, all had a uniformly fatal outcome.</p><p>There are less data on the use of <a class="drug drug_general" data-topicid="9537" href="/z/d/drug information/9537.html" rel="external">uridine triacetate</a> in patients who develop severe fluoropyrimidine toxicity because of deficiency in DPD or thymidylate synthetase  (<a class="graphic graphic_table graphicRef109665" href="/z/d/graphic/109665.html" rel="external">table 5</a>) [<a href="#rid83">83</a>]. (See  <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Predictive markers'</a>.)</p><p>However, the drug has been shown to prevent fatalities in mice that are treated with FU after receiving an inhibitor of DPD [<a href="#rid84">84</a>]. Thus, DPD enzyme-deficient patients who develop early, severe toxicity after receiving the first dose of a fluoropyrimidine should also benefit from treatment with <a class="drug drug_general" data-topicid="9537" href="/z/d/drug information/9537.html" rel="external">uridine triacetate</a>, if the deficiency is identified soon enough after the drug is administered. Uridine triacetate should not be administered for nonemergency toxicities as it may interfere with the efficacy of fluoropyrimidine treatment. (See  <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Management of DPD-deficient patients'</a>.)</p><p><a class="drug drug_general" data-topicid="9537" href="/z/d/drug information/9537.html" rel="external">Uridine triacetate</a> has received orphan drug designation for treatment of <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> or FU overexposure from the European Medicines Agency (EMA). In the United States, uridine triacetate is approved for emergency use following a FU or capecitabine overdose, regardless of the presence of symptoms, for patients who exhibit early onset, severe, or life-threatening toxicity affecting the cardiac or central nervous system, and/or early onset, unusually severe adverse reactions (eg, GI toxicity and/or neutropenia) within 96 hours following the end of FU or capecitabine administration [<a href="#rid85">85</a>]. There are reports, however, of patients with severe toxicity from FU or capecitabine responding to uridine triacetate administered beyond 96 hours after the last fluoropyrimidine dose [<a href="#rid81">81,86-88</a>]. In our view, uridine triacetate should be given to any patient with severe toxicity from fluoropyrimidine chemotherapy and suspected DPD or thymidylate synthetase enzyme deficiency regardless of the duration of time since the last dose of chemotherapy. The recommended <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D5a0ba417-8a4a-4d7f-b85a-1839ee8bd3f1&amp;token=RqWmwDhZAuWEPP%2FGQNAAHS48oMuMDwtw3bgs%2BlOH1OYI0TztZOhlhvZGSw9cBLURHACsC13Tbf%2BIe7dqek8rpYyEPpqlRlDpr4afujgJF%2ByccKdfK6dtXtaXg1tgjJNg&amp;TOPIC_ID=98342" target="_blank">dose and schedule for uridine triacetate</a> in adults is 10 g orally every six hours for 20 doses. The recommended dose and schedule for pediatric patients is 6.2 g/m<sup>2</sup> of body surface area, orally, every six hours for 20 doses.</p><p>Following recovery of unusually severe toxicity after the first dose of a fluoropyrimidine, testing for specific high-risk mutations/polymorphisms in the genes for DPD (<em>DPYD</em>) and thymidylate synthetase (<em>TYMS</em>) should be undertaken prior to retreatment with a fluoropyrimidine. (See  <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Testing for DPYD and TYMS variants'</a>.)</p><p class="headingAnchor" id="H1752923407"><span class="h2">Management of refractory patients</span><span class="headingEndMark"> — </span>For diarrhea that has not resolved after <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> and higher dose <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a>, gastroenterology should be consulted for upper endoscopy to include duodenal biopsy and aspirate [<a href="#rid15">15</a>]. Ulcers and erosions may indicate viral infection, such as cytomegalovirus (CMV), and should be biopsied. Duodenal aspirate can assess for small bowel bacterial overgrowth and parasitic infection [<a href="#rid15">15</a>]. For non-neutropenic patients with no signs of typhlitis, flexible sigmoidoscopy should be performed to assess for ulcerations indicative of CMV or plaques associated with <em>C. difficile</em>. Colonoscopy and flexible sigmoidoscopy are contraindicated in patients suspected of having neutropenic enterocolitis. (See <a class="local">'Neutropenic enterocolitis'</a> above.)</p><p>CMV is one of the most common causes of GI tract infection in patients treated with chemotherapy [<a href="#rid15">15</a>]. The esophagus and colon are the most common sites of infection within the GI tract. Clinical manifestations include diarrhea (up to 80 percent), bleeding, fever, and abdominal pain. Serology, viral cultures, and polymerase chain reaction (PCR) techniques may not be positive for three to four weeks after the start of symptoms [<a href="#rid15">15</a>]. Patients with severe ulcerations and immunosuppressed patients suspected of having CMV infection should be treated empirically with <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a>.</p><p class="headingAnchor" id="H665066359"><span class="h2">Restarting chemotherapy</span><span class="headingEndMark"> — </span>For most chemotherapy agents, treatment is routinely withheld for grade 2 or worse diarrhea and is only restarted after toxicity resolves. For many drugs with a high risk of CRD (eg, <a class="drug drug_general" data-topicid="121400" href="/z/d/drug information/121400.html" rel="external">alpelisib</a>, <a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">afatinib</a>, <a class="drug drug_general" data-topicid="95046" href="/z/d/drug information/95046.html" rel="external">ceritinib</a>), the United States Prescribing Information provides specific recommendations for dose reduction in subsequent cycles of therapy in individuals who have severe treatment-related toxicity, including diarrhea.</p><p>Guidelines about CRD published in response to septic deaths that occurred with weekly <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> chemotherapy concluded that patients must be free from diarrhea for at least 48 hours and not require antidiarrheals above baseline before retreatment with irinotecan [<a href="#rid13">13</a>]. This is a critical principle that, in our opinion, applies to treatment of patients with CRD due to any cytotoxic chemotherapy. Patients should be educated about the importance of not resuming chemotherapy until they have completely recovered from the CRD caused by the prior dose. The need for dose reduction should be addressed for any patient who develops grade 2 or worse diarrhea, particularly complicated diarrhea, during a prior cycle of therapy.</p><p class="headingAnchor" id="H2673825685"><span class="h1">PREVENTION</span></p><p class="headingAnchor" id="H2341958923"><span class="h2">Patient education</span><span class="headingEndMark"> — </span>Patients must be educated about the risk of severe diarrhea with certain chemotherapy regimens (particularly those containing <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> and <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> [FU]) and <a class="drug drug_general" data-topicid="114008" href="/z/d/drug information/114008.html" rel="external">neratinib</a> and about its management. Patients should be instructed to use <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> as directed by the oncologist's office and to not be limited by the package instructions. Loperamide is not absorbed but is excreted in stool, and the risk of overdose in the setting of CRD is unlikely [<a href="#rid15">15</a>]. Patients should be instructed and encouraged to call with any concerns, including diarrhea that does not respond to six to eight loperamide tablets in a 24 hour period, abdominal cramping, and fever. The potential need for in-person assessment, intravenous fluids, and antibiotics should be explained.</p><p class="headingAnchor" id="H3019649757"><span class="h2">Pharmacogenetic and pharmacokinetic testing</span><span class="headingEndMark"> — </span>Strategies to reduce CRD include initial dosing of <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> based on uridine diphosphoglucuronate-glucuronosyltransferase 1A1 (<em>UGT1A1)</em> genotype (individuals who are homozygous for the UGT1A1*28 allele are at increased risk for neutropenia and diarrhea following treatment), pharmacogenetic testing for mutations and polymorphisms in the fluoropyrimidine-metabolizing enzymes dihydropyrimidine dehydrogenase (DPD) and thymidylate synthetase, and pharmacokinetically guided dosing of FU. However, none of these approaches has been widely adopted. (See  <a class="medical medical_review" href="/z/d/html/83810.html" rel="external">"Dosing of anticancer agents in adults", section on 'UGT1A1 polymorphisms and irinotecan'</a> and  <a class="medical medical_review" href="/z/d/html/83810.html" rel="external">"Dosing of anticancer agents in adults", section on 'Fluoropyrimidines, dihydropyrimidine dehydrogenase, and thymidylate synthase variants'</a> and  <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Testing for DPYD and TYMS variants'</a> and  <a class="medical medical_review" href="/z/d/html/83810.html" rel="external">"Dosing of anticancer agents in adults", section on 'Therapeutic drug monitoring'</a>.)</p><p>However, one exception is that patients who have a history of unconjugated hyperbilirubinemia without an identifiable cause, such as hemolysis, typically have Gilbert syndrome. Patients with Gilbert syndrome have a defect in the promoter of the gene that encodes <em>UGT1A1</em>, which is responsible for the conjugation of bilirubin with glucuronic acid. The UGT1A1 protein also conjugates SN-38, the active metabolite of <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> [<a href="#rid89">89</a>], to glucuronic acid. Gilbert syndrome manifests clinically in homozygous carriers of this mutation, but heterozygotes will also have elevated bilirubin levels. We recommend an initial dose reduction (eg, 25 percent) of irinotecan for patients who have known or suspected Gilbert syndrome based on a history of elevated unconjugated bilirubin without another cause. (See  <a class="medical medical_review" href="/z/d/html/3578.html" rel="external">"Gilbert syndrome"</a>.)</p><p class="headingAnchor" id="H524528755"><span class="h2">Is there a role for prophylaxis?</span><span class="headingEndMark"> — </span>Prophylactic antidiarrheal treatment is recommended during the first two cycles of <a class="drug drug_general" data-topicid="114008" href="/z/d/drug information/114008.html" rel="external">neratinib</a>, to reduce the incidence and severity of treatment-related diarrhea. Prophylactic antidiarrhea treatment is not a standard approach for any other chemotherapy regimen.</p><p class="headingAnchor" id="H964242162"><span class="h3">Neratinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="114008" href="/z/d/drug information/114008.html" rel="external">Neratinib</a> is an orally active, irreversible tyrosine kinase inhibitor of several epidermal growth factor receptors, including HER1, HER2, and HER4; it is approved for extended adjuvant therapy in early stage HER2-positive breast cancer, and in combination with <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> for advanced HER2-positive breast cancer. (See  <a class="medical medical_review" href="/z/d/html/773.html" rel="external">"Adjuvant systemic therapy for HER2-positive breast cancer", section on 'Dual anti-HER2 therapy in high-risk disease'</a>.)</p><p>Treatment-related diarrhea occurs in almost all treated patients, and it is severe (grade 3 or 4) in approximately 40 percent. Antidiarrheal prophylaxis has been shown to reduce both the incidence and severity of neratinib-induced diarrhea [<a href="#rid90">90,91</a>]. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Dd1e41dcf-e82a-47c2-a0ad-6c6eef621834&amp;token=1j%2BgeR2kXTm%2FK03NUPvTUbH%2BoXvZNA%2FBofftSXKg21OKqIYHkj%2FnmIXw0Ju04KO%2FtE6CkfxXiaCRZeXjs4e2CfaXh7%2BhqbEp%2Bwf%2Fk2PTHOALreFjSHW26WEjRajNDZ38&amp;TOPIC_ID=98342" target="_blank">United States Prescribing Information for neratinib</a> recommends prophylactic <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> (4 mg three times a day during the first two weeks of therapy initiated with the first dose, then 4 mg twice daily during weeks three to eight until day 56, and thereafter, titration of the dose to maintain one to two bowel movements per day [<a href="#rid91">91</a>]). <a class="drug drug_general" data-topicid="114008" href="/z/d/drug information/114008.html" rel="external">Neratinib</a> dose modifications for grade 2 to 4 diarrhea despite the use of loperamide are also included in the prescribing information.</p><p class="headingAnchor" id="H3473078820"><span class="h3">Other regimens</span><span class="headingEndMark"> — </span>A variety of approaches have been explored for primary antidiarrheal therapy prophylaxis in patients treated with a variety of other high-risk regimens, mostly bolus FU plus <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> and irinotecan-containing. There is insufficient evidence to support a recommendation for any of these treatments, and for most patients we suggest not pursuing any of these approaches. One scenario where long-acting <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> (octreotide LAR) might be considered is for secondary prophylaxis in patients who have experienced severe CRD during a prior cycle of chemotherapy, in order to maintain dose intensity.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Octreotide</strong> – In contrast to its therapeutic benefit, the role of prophylactic <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> is unproven [<a href="#rid77">77,78,92,93</a>]. In the only randomized study to compare octreotide long-acting release (LAR) with a no-treatment control arm in 139 patients receiving chemotherapy for colorectal cancer with FU, <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a>, and/or <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>, octreotide LAR did not prevent or reduce the severity of CRD [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent1">However, one scenario where <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> LAR might be considered is for secondary prophylaxis in patients who have experienced severe CRD during a prior cycle of chemotherapy, in order to maintain dose intensity. The benefit of this approach was suggested in a study, which closed early due to poor accrual of patients who experienced grade 2 or higher diarrhea with an initial cycle of chemotherapy; treatment was continued with a 25 percent reduction in the chemotherapy dose plus the addition of octreotide 30 mg LAR intramuscular injection monthly [<a href="#rid78">78</a>]. Patients who did not experience grade 2 or higher diarrhea with the second cycle could resume full-dose chemotherapy with continuation of the octreotide. Ten of the 29 patients assigned to this approach were able to resume full-dose chemotherapy without severe diarrhea. No patient experienced adverse events related to octreotide that were greater than grade 1. This approach should only be considered if diarrhea is the only dose-limiting toxicity, and only if maintaining dose intensity is clinically important. (See <a class="local">'Octreotide'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Activated charcoal</strong> – Activated charcoal may have a role in preventing irinotecan-induced diarrhea [<a href="#rid94">94</a>]. In one study, 28 patients received activated charcoal during the first treatment cycle but not the second. The incidence of grade 3 or 4 diarrhea increased from 7 to 25 percent between cycles 1 and 2, and more patients required 10 or more tablets of <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> without prophylaxis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral alkalinization</strong> – A complicated regimen of oral alkalinization of the intestinal lumen in conjunction with control of defecation may have been beneficial in a Japanese case-control study of patients undergoing <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> chemotherapy [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Probiotics</strong> – An interesting but investigational strategy is oral administration of "probiotics," microorganisms such as the <a class="drug drug_general" data-topicid="9541" href="/z/d/drug information/9541.html" rel="external">Lactobacillus</a> species. Based on the success of this approach in children afflicted by diarrheal illnesses, as well as for antibiotic-induced diarrhea, a trial was conducted in 150 patients receiving two different FU-based chemotherapy regimens, in which the random assignment was to receive or not receive <em>Lactobacillus rhamnosus </em>GG and/or fiber supplementation [<a href="#rid96">96</a>]. Patients who received Lactobacillus supplements had significantly less grade 3 and 4 diarrhea (22 versus 37 percent) and required fewer hospitalizations and dose reductions due to bowel toxicity. However, this group also had a trend toward a higher number of neutropenic complications. Fiber intake did not alter chemotherapy toxicity. Interpretation of this trial is limited by the lack of stratification for method of chemotherapy administration. A randomized, placebo-controlled trial of probiotics for patients treated with <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> was closed early for poor accrual. Among the 46 patients enrolled, those on probiotics had less diarrhea and less severe diarrhea, but the results are not statistically significant [<a href="#rid97">97</a>]. Further studies are needed to assess the overall benefit of such interventions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Racecadotril</strong> – A randomized phase II trial demonstrated no benefit for the enkephalinase inhibitor racecadotril to prevent or diminish the severity of delayed diarrhea in patients treated with <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> [<a href="#rid98">98</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lafutidine</strong> – Lafutidine is a histamine antagonist that has been shown to reduce FU-induced mucosal injury [<a href="#rid99">99</a>]. Twenty-two patients with resected stage II or III gastric cancer were randomly assigned to adjuvant S1 chemotherapy or S1 plus lafutidine. The addition of lafutidine to chemotherapy significantly reduced the overall incidence of diarrhea from 83 to 10 percent (p = 0.002) [<a href="#rid100">100</a>]. Larger studies are needed to confirm these findings.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcium aluminosilicate clay</strong> – Calcium aluminosilicate clay, a cation exchange absorbent, did not prevent severe irinotecan-induced diarrhea in a randomized trial of 100 patients [<a href="#rid101">101</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Budesonide</strong> – <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">Budesonide</a> is an orally administered, topically active synthetic steroid with proven efficacy in patients suffering from diarrhea caused by inflammatory bowel disease and collagenous colitis. A prospective, double-blind, placebo-controlled, randomized phase III study in 56 patients receiving <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> failed to show a significant protective benefit, although there were some trends toward fewer diarrhea episodes (0.7 versus 2.2), a shorter duration of diarrhea (1.8 versus 4.2 days), and less frequent use of <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> (42 versus 56 percent) with budesonide. Larger studies are needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Palifermin</strong> – <a class="drug drug_general" data-topicid="10161" href="/z/d/drug information/10161.html" rel="external">Palifermin</a>, a keratinocyte growth factor, administered intravenously for three days before and after chemotherapy was found to reduce severe diarrhea from 26 to 8 percent (p = 0.01) in 155 patients with acute myelogenous leukemia undergoing induction chemotherapy [<a href="#rid102">102</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glutamine</strong> – Whether <a class="drug drug_general" data-topicid="8747" href="/z/d/drug information/8747.html" rel="external">glutamine</a> is beneficial to prevent CRD is unclear; studies have had mixed results [<a href="#rid103">103-107</a>]. In three studies, glutamine (oral in two, parenteral in one) did not reduce the incidence of severe diarrhea in patients undergoing chemoradiation for rectal cancer [<a href="#rid103">103</a>], in patients receiving leucovorin-modulated FU chemotherapy for colorectal cancer [<a href="#rid107">107</a>], or in breast cancer patients treated with doxifluridine [<a href="#rid105">105</a>]. On the other hand, modest benefit was suggested in a small (n = 70), randomized, placebo-controlled trial in which oral glutamine (18 g/day) administered prophylactically to patients treated with leucovorin-modulated FU decreased the duration of diarrhea but had no significant impact on severity; treated patients also took fewer <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> tablets after one cycle of chemotherapy (0.4 versus 2.6) [<a href="#rid104">104</a>].</p><p></p><p class="headingAnchor" id="H965169655"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Highest-risk agents</strong> – Chemotherapy-related diarrhea (CRD) is a common problem in cancer patients and is most often described with fluoropyrimidines; <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>; and several molecularly targeted agents, especially <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a>, <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">afatinib</a>, <a class="drug drug_general" data-topicid="95046" href="/z/d/drug information/95046.html" rel="external">ceritinib</a> <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">lapatinib</a>, and <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a>. In addition, immune checkpoint inhibitors (<a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>, <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>, and <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>) cause an immune-mediated colitis. (See  <a class="medical medical_review" href="/z/d/html/138429.html" rel="external">"Immune checkpoint inhibitor colitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CRD typically begins with an increasing frequency of bowel movements and/or a loosening of stool consistency, commonly accompanied by excessive gas and/or intestinal cramping. As the CRD progresses, it can become severe, with frequent watery stools.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CRD can be debilitating and, in some cases, life-threatening; hospital admission is frequently needed for adequate supportive care. Other sequelae include reduced quality of life, treatment delay, and diminished compliance with treatment regimens, which may compromise long-term outcomes if the chemotherapy is being administered with curative intent. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with CRD should be assessed for number of stools and stool composition (and if relevant, the volume and consistency of ostomy output)  (<a class="graphic graphic_table graphicRef65649" href="/z/d/graphic/65649.html" rel="external">table 1</a>), as well as for symptoms or signs that suggest "complicated" diarrhea, such as cramping, grade 2 or worse  (<a class="graphic graphic_table graphicRef69015" href="/z/d/graphic/69015.html" rel="external">table 3</a>) nausea or vomiting, decreased performance status, fever, dizziness, hypotension, neutropenia, bleeding, dehydration, chest pain, and prior admission for CRD. (See <a class="local">'History and physical examination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who develop diarrhea during chemotherapy may also suffer from organic causes, which may or may not be related to the chemotherapy and should not be overlooked. These include small intestinal bacterial overgrowth, fat or bile acid malabsorption, intake of excess quantities of <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">sorbitol</a> or lactose intolerance, inflammatory and infectious causes, stool impaction, and collagenous colitis. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Site and urgency of care</strong> – Evaluation and management depends on severity and whether exacerbating factors are present  (<a class="graphic graphic_algorithm graphicRef64251" href="/z/d/graphic/64251.html" rel="external">algorithm 1</a>). Most patients with severe (grade 3 or 4) diarrhea, as well as those with grade 1 or 2 complicated diarrhea, require admission for intravenous fluids, monitoring of cardiovascular status, and serial assessment of electrolytes. However, patients with grade 3 diarrhea that has not yet been treated adequately with <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> and who are well hydrated may be managed at home with serial assessment for response to therapy and development of complications that might indicate the need for hospitalization or targeted therapy. (See <a class="local">'Management according to the severity of diarrhea and other exacerbating factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Investigations</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Laboratory testing should address both the complications and causes of CRD. These include a complete blood count and a standard chemistry screen including magnesium. For patients with severe (grade 3 or 4) diarrhea, persistent mild to moderate (grade 1 or 2) diarrhea, or diarrhea accompanied by neutropenia, fever, or blood in the stools, cultures of blood and stool, and diagnostic testing for toxin-producing strains of <em>C. difficile</em> are indicated</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with fever, peritoneal signs, or bloody diarrhea should also have an urgent CT scan of the abdomen and pelvis, and surgical consultation.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Endoscopy is not indicated in the vast majority of cases but should be considered for refractory cases and for patients who develop chronic diarrhea (ie, diarrhea that persists throughout the entire chemotherapy cycle) or bloody diarrhea. (See <a class="local">'Lymphocytic colitis'</a> above and <a class="local">'Management of refractory patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonpharmacologic measures</strong> – Initial nonpharmacologic measures include avoidance of foods that might aggravate the diarrhea  (<a class="graphic graphic_table graphicRef57475" href="/z/d/graphic/57475.html" rel="external">table 2</a>); aggressive oral rehydration with fluids that contain water, salt, and sugar, such as broth or Gatorade; and either a clear liquid diet or a BRAT (bananas, rice, applesauce, and toast) diet. Patients should be instructed to avoid alcohol, caffeine, and lactose-containing foods  (<a class="graphic graphic_table graphicRef54826" href="/z/d/graphic/54826.html" rel="external">table 4</a>), and to stop other medications and supplements that could cause diarrhea, such as stool softeners, laxatives, milk thistle, aloe, saw palmetto, Siberian ginseng, plantago seeds, coenzyme Q10, high doses of <a class="drug drug_general" data-topicid="9776" href="/z/d/drug information/9776.html" rel="external">vitamin C</a>, and green tea. (See <a class="local">'General measures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pharmacologic therapy</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We recommend <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> rather than <a class="drug drug_general" data-topicid="9370" href="/z/d/drug information/9370.html" rel="external">diphenoxylate-atropine</a> for initial therapy of CRD (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). For mild to moderate (grade 1 or 2) uncomplicated CRD, we suggest an initial dose of 4 mg, followed by 2 mg every four hours or 2 mg after each loose stool (no more than 16 mg per day) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with severe (grade 3 or 4) diarrhea, mild to moderate diarrhea that is complicated by moderate to severe abdominal cramping, grade 2 or worse nausea/vomiting  (<a class="graphic graphic_table graphicRef69015" href="/z/d/graphic/69015.html" rel="external">table 3</a>), decreased performance status, fever, sepsis, neutropenia, frank bleeding, dehydration, or mild to moderate uncomplicated diarrhea that persists after 24 hours of <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a>, we suggest high-dose loperamide (4 mg initially, followed by 2 mg every two hours, no more than 16 mg daily) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Loperamide and diphenoxylate-atropine'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We recommend <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> for any patient with CRD that is refractory to <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). We suggest initiating therapy at 100 or 150 mcg subcutaneously three times daily (or 50 to 150 mcg/hour intravenously). The octreotide dose should be rapidly escalated to 500 mcg subcutaneously three times a day (rarely up to 2000 mcg three times a day) if lower doses are not effective. (See <a class="local">'Patients refractory to loperamide'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For fluoropyrimidine-treated patients who develop severe diarrhea after the initial dose, in conjunction with severe myelosuppression, mucositis, cardiotoxicity, or neurotoxicity, or after an unintentional overdose, who are identified within 96 hours of the last chemotherapy dose, we recommend <a class="drug drug_general" data-topicid="9537" href="/z/d/drug information/9537.html" rel="external">uridine triacetate</a> (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). For individuals with ongoing severe fluoropyrimidine-related toxicity (diarrhea, myelosuppression, mucositis, cardiotoxicity, or neurotoxicity) who are identified later than 96 hours after the last chemotherapy dose, we also suggest initiation of uridine triacetate (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Uridine triacetate'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>There is no consensus on the appropriate role for oral antibiotics in patients with CRD. We would start intravenous antibiotics for patients with fever, neutropenia, hypotension, peritoneal signs, or bloody diarrhea. (See <a class="local">'Oral antibiotics'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For refractory cases, empiric anti-cytomegalovirus therapy may be needed for selected patients who have severe ulceration in the upper or lower gastrointestinal tract. (See <a class="local">'Management of refractory patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rechallenge</strong> – Patients who experience CRD should not be retreated with the same chemotherapy regimen until they are diarrhea-free without the use of antidiarrheal agents for 48 hours. The need for dose reduction should be addressed in any patient who develops grade 2 or worse diarrhea, particularly complicated diarrhea, during a prior cycle of therapy. (See <a class="local">'Restarting chemotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prophylaxis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients receiving <a class="drug drug_general" data-topicid="114008" href="/z/d/drug information/114008.html" rel="external">neratinib</a>, we recommend daily prophylactic <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a>, at least for the first eight weeks of therapy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Neratinib'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A variety of approaches have been explored for primary antidiarrheal therapy prophylaxis in patients treated with a variety of other high-risk regimens, mostly bolus FU plus <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> and irinotecan-containing, but there is insufficient evidence to support a recommendation for any of these treatments, and for most patients we suggest not pursuing any of these approaches (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One scenario where long-acting <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> (octreotide LAR) might be considered is for secondary prophylaxis in patients who have experienced severe CRD as the only dose-limiting toxicity during a prior cycle of chemotherapy, if maintaining dose intensity is critical. (See <a class="local">'Is there a role for prophylaxis?'</a> above.)</p><p></p><p class="headingAnchor" id="H1043710876"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Smitha S Krishnamurthi, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Tabernero J, Van Cutsem E, Lakomý R, et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 2014; 50:320.</a></li><li><a class="nounderline abstract_t">Folprecht G, Pericay C, Saunders MP, et al. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. Ann Oncol 2016; 27:1273.</a></li><li><a class="nounderline abstract_t">Massard C, Gordon MS, Sharma S, et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol 2016; 34:3119.</a></li><li><a class="nounderline abstract_t">Garassino MC, Cho BC, Kim JH, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol 2018; 19:521.</a></li><li><a class="nounderline abstract_t">Ikuno N, Soda H, Watanabe M, Oka M. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 1995; 87:1876.</a></li><li><a class="nounderline abstract_t">Parnes HL, Fung E, Schiffer CA. Chemotherapy-induced lactose intolerance in adults. Cancer 1994; 74:1629.</a></li><li><a class="nounderline abstract_t">Osterlund P, Ruotsalainen T, Peuhkuri K, et al. Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer. Clin Gastroenterol Hepatol 2004; 2:696.</a></li><li><a class="nounderline abstract_t">Abigerges D, Chabot GG, Armand JP, et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995; 13:210.</a></li><li><a class="nounderline abstract_t">Dranitsaris G, Maroun J, Shah A. Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy-induced diarrhea. Can J Gastroenterol 2005; 19:83.</a></li><li><a class="nounderline abstract_t">Arbuckle RB, Huber SL, Zacker C. The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. Oncologist 2000; 5:250.</a></li><li><a class="nounderline abstract_t">Carlotto A, Hogsett VL, Maiorini EM, et al. The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue. Pharmacoeconomics 2013; 31:753.</a></li><li><a class="nounderline abstract_t">Elting LS, Shih YC. The economic burden of supportive care of cancer patients. Support Care Cancer 2004; 12:219.</a></li><li><a class="nounderline abstract_t">Benson AB 3rd, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004; 22:2918.</a></li><li><a class="nounderline abstract_t">Mertz HR, Beck CK, Dixon W, et al. Validation of a new measure of diarrhea. Dig Dis Sci 1995; 40:1873.</a></li><li><a class="nounderline abstract_t">Andreyev J, Ross P, Donnellan C, et al. Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol 2014; 15:e447.</a></li><li><a class="nounderline abstract_t">O'Brien BE, Kaklamani VG, Benson AB 3rd. The assessment and management of cancer treatment-related diarrhea. Clin Colorectal Cancer 2005; 4:375.</a></li><li><a class="nounderline abstract_t">Khoshini R, Dai SC, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci 2008; 53:1443.</a></li><li><a class="nounderline abstract_t">Smith GM, Chesner IM, Asquith P, Leyland MJ. Small intestinal bacterial overgrowth in patients with chronic lymphocytic leukaemia. J Clin Pathol 1990; 43:57.</a></li><li><a class="nounderline abstract_t">Wedlake L, Thomas K, McGough C, Andreyev HJ. Small bowel bacterial overgrowth and lactose intolerance during radical pelvic radiotherapy: An observational study. Eur J Cancer 2008; 44:2212.</a></li><li><a class="nounderline abstract_t">Grace E, Shaw C, Whelan K, Andreyev HJ. Review article: small intestinal bacterial overgrowth--prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther 2013; 38:674.</a></li><li><a class="nounderline abstract_t">Grigg AP, Angus PW, Hoyt R, Szer J. The incidence, pathogenesis and natural history of steatorrhea after bone marrow transplantation. Bone Marrow Transplant 2003; 31:701.</a></li><li><a class="nounderline abstract_t">Phillips F, Muls AC, Lalji A, Andreyev HJ. Are bile acid malabsorption and bile acid diarrhoea important causes of loose stool complicating cancer therapy? Colorectal Dis 2015; 17:730.</a></li><li><a class="nounderline abstract_t">Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993; 17:109.</a></li><li><a class="nounderline abstract_t">Emoto M, Kawarabayashi T, Hachisuga MD, et al. Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. Gynecol Oncol 1996; 61:369.</a></li><li><a class="nounderline abstract_t">Kamthan AG, Bruckner HW, Hirschman SZ, Agus SG. Clostridium difficile diarrhea induced by cancer chemotherapy. Arch Intern Med 1992; 152:1715.</a></li><li><a class="nounderline abstract_t">Husain A, Aptaker L, Spriggs DR, Barakat RR. Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens. Gynecol Oncol 1998; 71:104.</a></li><li><a class="nounderline abstract_t">Aksoy DY, Tanriover MD, Uzun O, et al. Diarrhea in neutropenic patients: a prospective cohort study with emphasis on neutropenic enterocolitis. Ann Oncol 2007; 18:183.</a></li><li><a class="nounderline abstract_t">Krishna SG, Zhao W, Grazziutti ML, et al. Incidence and risk factors for lower alimentary tract mucositis after 1529 courses of chemotherapy in a homogenous population of oncology patients: clinical and research implications. Cancer 2011; 117:648.</a></li><li><a class="nounderline abstract_t">Ibrahim NK, Sahin AA, Dubrow RA, et al. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet 2000; 355:281.</a></li><li><a class="nounderline abstract_t">Kreis W, Petrylak D, Savarese D, Budman D. Colitis and docetaxel-based chemotherapy. Lancet 2000; 355:2164.</a></li><li><a class="nounderline abstract_t">Ghiringhelli F, Vincent J, Beltjens F, et al. Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients. Invest New Drugs 2015; 33:1263.</a></li><li><a class="nounderline abstract_t">DuPont HL. Guidelines on acute infectious diarrhea in adults. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1997; 92:1962.</a></li><li><a class="nounderline abstract_t">Vinther S, Rumessen JJ, Christensen M. [Pharmaceutical drugs containing lactose can as a rule be used by persons with lactose intolerance]. Ugeskr Laeger 2015; 177.</a></li><li><a class="nounderline abstract_t">Eadala P, Waud JP, Matthews SB, et al. Quantifying the 'hidden' lactose in drugs used for the treatment of gastrointestinal conditions. Aliment Pharmacol Ther 2009; 29:677.</a></li><li><a class="nounderline abstract_t">Regnard C, Twycross R, Mihalyo M, Wilcock A. Loperamide. J Pain Symptom Manage 2011; 42:319.</a></li><li><a class="nounderline abstract_t">Awouters F, Megens A, Verlinden M, et al. Loperamide. Survey of studies on mechanism of its antidiarrheal activity. Dig Dis Sci 1993; 38:977.</a></li><li><a class="nounderline abstract_t">Shannon HE, Lutz EA. Comparison of the peripheral and central effects of the opioid agonists loperamide and morphine in the formalin test in rats. Neuropharmacology 2002; 42:253.</a></li><li><a class="nounderline abstract_t">Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil 2004; 16 Suppl 2:17.</a></li><li><a class="nounderline abstract_t">Ooms LA, Degryse AD, Janssen PA. Mechanisms of action of loperamide. Scand J Gastroenterol Suppl 1984; 96:145.</a></li><li><a class="nounderline abstract_t">Penfold D, Volans GN. Overdose from Lomotil. Br Med J 1977; 2:1401.</a></li><li><a class="nounderline abstract_t">Pelemans W, Vantrappen F. A double blind crossover comparison of loperamide with diphenoxylate in the symptomatic treatment of chronic diarrhea. Gastroenterology 1976; 70:1030.</a></li><li><a class="nounderline abstract_t">Amery W, Duyck F, Polak J, van den Bouwhuysen G. A multicentre double-blind study in acute diarrhoea comparing loperamide (R 18553) with two common antidiarrhoeal agents and a placebo. Curr Ther Res Clin Exp 1975; 17:263.</a></li><li class="breakAll">Cornett JWD, Aspeling RL and Mallegol D. A double-blind comparative evaluation of loperamide versus diphenoxylate with atropine for acute diarrhea. Curr Therapeutic Res 1977; 21:629.</li><li><a class="nounderline abstract_t">Dom J, Leyman R, Schuermans V, Brugmans J. Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 8: Clinical investigation. Use of a flexible dosage schedule in a double-blind comparison of loperamide with diphenoxylate in 614 patients suffering from acute diarrhea. Arzneimittelforschung 1974; 24:1660.</a></li><li><a class="nounderline abstract_t">Verhaegen H, De Cree J, Schuermans V. Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 7: Clinical investigation. Efficacy and safety of loperamide in patients with severe chronic diarrhea. Arzneimittelforschung 1974; 24:1657.</a></li><li><a class="nounderline abstract_t">Jaffé G. A comparison of lomotil and imodium in acute non-specific diarrhoea. J Int Med Res 1977; 5:195.</a></li><li><a class="nounderline abstract_t">Bergman L, Djärv L. A comparative study of loperamide and diphenoxylate in the treatment of chronic diarrhoea caused by intestinal resection. Ann Clin Res 1981; 13:402.</a></li><li><a class="nounderline abstract_t">Palmer KR, Corbett CL, Holdsworth CD. Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea. Gastroenterology 1980; 79:1272.</a></li><li><a class="nounderline abstract_t">Shee CD, Pounder RE. Loperamide, diphenoxylate, and codeine phosphate in chronic diarrhoea. Br Med J 1980; 280:524.</a></li><li><a class="nounderline abstract_t">Vehreschild MJ, Vehreschild JJ, Hübel K, et al. Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Oncol 2013; 24:1189.</a></li><li><a class="nounderline abstract_t">Maroun JA, Anthony LB, Blais N, et al. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Curr Oncol 2007; 14:13.</a></li><li><a class="nounderline abstract_t">Lavö B, Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study. Scand J Gastroenterol Suppl 1987; 130:77.</a></li><li><a class="nounderline abstract_t">Tijtgat GN, Meuwissen SG, Huibregtse K. Loperamide in the symptomatic control of chronic diarrhoea. Double-blind placebo-controlled study. Ann Clin Res 1975; 7:325.</a></li><li><a class="nounderline abstract_t">Mainguet P, Fiasse R. Double-blind placebo-controlled study of loperamide (Imodium) in chronic diarrhoea caused by ileocolic disease or resection. Gut 1977; 18:575.</a></li><li><a class="nounderline abstract_t">Galambos JT, Hersh T, Schroder S, Wenger J. Loperamide: a new antidiarrheal agent in the treatment of chronic diarrhea. Gastroenterology 1976; 70:1026.</a></li><li><a class="nounderline abstract_t">Petrelli NJ, Rodriguez-Bigas M, Rustum Y, et al. Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma. Cancer 1993; 72:1543.</a></li><li><a class="nounderline abstract_t">Cascinu S, Fedeli A, Fedeli SL, Catalano G. Control of chemotherapy-induced diarrhoea with octreotide in patients receiving 5-fluorouracil. Eur J Cancer 1992; 28:482.</a></li><li><a class="nounderline abstract_t">Mercadante S. Diarrhea in terminally ill patients: pathophysiology and treatment. J Pain Symptom Manage 1995; 10:298.</a></li><li><a class="nounderline abstract_t">Cascinu S, Bichisao E, Amadori D, et al. High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients. Support Care Cancer 2000; 8:65.</a></li><li><a class="nounderline abstract_t">Cascinu S, Fedeli A, Fedeli SL, Catalano G. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol 1993; 11:148.</a></li><li><a class="nounderline abstract_t">Teigeler T, Stahura H, Alimohammad R, et al. Electrocardiographic changes in loperamide toxicity: Case report and review of literature. J Cardiovasc Electrophysiol 2019; 30:2618.</a></li><li><a class="nounderline abstract_t">Eggleston W, Palmer R, Dubé PA, et al. Loperamide toxicity: recommendations for patient monitoring and management. Clin Toxicol (Phila) 2020; 58:355.</a></li><li class="breakAll">FDA Drug Safety Communication: FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium), including from abuse and misuse. Food and Drug Administration. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-serious-heart-problems-high-doses-antidiarrheal (Accessed on July 06, 2022).</li><li><a class="nounderline abstract_t">Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334:246.</a></li><li><a class="nounderline abstract_t">Edwards C, Cann PA, Read NW, Holdsworth CD. Effect of two new antisecretory drugs on fluid and electrolyte transport in a patient with secretory diarrhoea. Gut 1986; 27:581.</a></li><li><a class="nounderline abstract_t">Dueno MI, Bai JC, Santangelo WC, Krejs GJ. Effect of somatostatin analog on water and electrolyte transport and transit time in human small bowel. Dig Dis Sci 1987; 32:1092.</a></li><li><a class="nounderline abstract_t">Maton PN, O'Dorisio TM, Howe BA, et al. Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera. N Engl J Med 1985; 312:17.</a></li><li><a class="nounderline abstract_t">Wadler S, Haynes H, Wiernik PH. Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea. J Clin Oncol 1995; 13:222.</a></li><li><a class="nounderline abstract_t">Topkan E, Karaoglu A. Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma. Oncology 2006; 71:354.</a></li><li><a class="nounderline abstract_t">Barbounis V, Koumakis G, Vassilomanolakis M, et al. Control of irinotecan-induced diarrhea by octreotide after loperamide failure. Support Care Cancer 2001; 9:258.</a></li><li><a class="nounderline abstract_t">Zidan J, Haim N, Beny A, et al. Octreotide in the treatment of severe chemotherapy-induced diarrhea. Ann Oncol 2001; 12:227.</a></li><li><a class="nounderline abstract_t">Bhattacharya S, Vijayasekar C, Worlding J, Mathew G. Octreotide in chemotherapy induced diarrhoea in colorectal cancer: a review article. Acta Gastroenterol Belg 2009; 72:289.</a></li><li><a class="nounderline abstract_t">Harris AG, O'Dorisio TM, Woltering EA, et al. Consensus statement: octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel. Dig Dis Sci 1995; 40:1464.</a></li><li><a class="nounderline abstract_t">Goumas P, Naxakis S, Christopoulou A, et al. Octreotide Acetate in the Treatment of Fluorouracil-Induced Diarrhea. Oncologist 1998; 3:50.</a></li><li><a class="nounderline abstract_t">Gebbia V, Carreca I, Testa A, et al. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. Anticancer Drugs 1993; 4:443.</a></li><li><a class="nounderline abstract_t">Rosenoff S. Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies. Support Care Cancer 2004; 12:561.</a></li><li><a class="nounderline abstract_t">Rosenoff SH, Gabrail NY, Conklin R, et al. A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial. J Support Oncol 2006; 4:289.</a></li><li><a class="nounderline abstract_t">VAN DEN Heuvel B, Peeters M, Hendlisz A, et al. Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea: proof of concept. Minerva Chir 2016.</a></li><li><a class="nounderline abstract_t">Saliba F, Hagipantelli R, Misset JL, et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol 1998; 16:2745.</a></li><li><a class="nounderline abstract_t">Lenfers BH, Loeffler TM, Droege CM, Hausamen TU. Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. Ann Oncol 1999; 10:1251.</a></li><li><a class="nounderline abstract_t">Ma WW, Saif MW, El-Rayes BF, et al. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. Cancer 2017; 123:345.</a></li><li><a class="nounderline abstract_t">Ison G, Beaver JA, McGuinn WD Jr, et al. FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs. Clin Cancer Res 2016; 22:4545.</a></li><li class="breakAll">Ma WW, Saif WM, El-Rayes BF, et al. Clinical trial experience with uridine triacetate for 5-fluorouracil toxicity (abstract). J Clin Oncol 34, 2016 (suppl 4S; abstr 655). http://meetinglibrary.asco.org/content/159120-173 (Accessed on February 04, 2016).</li><li class="breakAll">von Borstel R, O'Neil JD, Saydoff JA, et al. Uridine triacetate for lethal 5-FU toxicity due to dihydropyrimidine dehydrogenase (DPD) deficiency (abstract). J Clin Oncol 2010 (suppl abstract e13505).</li><li class="breakAll">http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm476930.htm (Accessed on December 14, 2015).</li><li><a class="nounderline abstract_t">Baldeo C, Vishnu P, Mody K, Kasi PM. Uridine triacetate for severe 5-fluorouracil toxicity in a patient with thymidylate synthase gene variation: Potential pharmacogenomic implications. SAGE Open Med Case Rep 2018; 6:2050313X18786405.</a></li><li><a class="nounderline abstract_t">Zurayk M, Keung YK, Yu D, Hu EH. Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature. J Oncol Pharm Pract 2019; 25:234.</a></li><li><a class="nounderline abstract_t">Jacob A, Sekkath Veedu J, Selene I, et al. Case report: Uridine triacetate in the management of delayed onset 5-fluorouracil toxicity: A case report and review of literature. Front Pharmacol 2022; 13:977734.</a></li><li><a class="nounderline abstract_t">Iyer L, Hall D, Das S, et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 1999; 65:576.</a></li><li><a class="nounderline abstract_t">Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017; 18:1688.</a></li><li><a class="nounderline abstract_t">Barcenas CH, Hurvitz SA, Di Palma JA, et al. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. Ann Oncol 2020; 31:1223.</a></li><li><a class="nounderline abstract_t">Meropol NJ, Blumenson LE, Creaven PJ. Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin. Am J Clin Oncol 1998; 21:135.</a></li><li><a class="nounderline abstract_t">Hoff PM, Saragiotto DF, Barrios CH, et al. Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial. J Clin Oncol 2014; 32:1006.</a></li><li><a class="nounderline abstract_t">Michael M, Brittain M, Nagai J, et al. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. J Clin Oncol 2004; 22:4410.</a></li><li><a class="nounderline abstract_t">Takeda Y, Kobayashi K, Akiyama Y, et al. Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients. Int J Cancer 2001; 92:269.</a></li><li><a class="nounderline abstract_t">Osterlund P, Ruotsalainen T, Korpela R, et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer 2007; 97:1028.</a></li><li><a class="nounderline abstract_t">Mego M, Chovanec J, Vochyanova-Andrezalova I, et al. Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study. Complement Ther Med 2015; 23:356.</a></li><li><a class="nounderline abstract_t">Ychou M, Douillard JY, Rougier P, et al. Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study. Am J Clin Oncol 2000; 23:143.</a></li><li><a class="nounderline abstract_t">Saegusa Y, Ichikawa T, Iwai T, et al. Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis. Scand J Gastroenterol 2008; 43:531.</a></li><li><a class="nounderline abstract_t">Namikawa T, Munekage E, Maeda H, et al. Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer. Anticancer Res 2014; 34:7297.</a></li><li><a class="nounderline abstract_t">Kee BK, Morris JS, Slack RS, et al. A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan. Support Care Cancer 2015; 23:661.</a></li><li><a class="nounderline abstract_t">Bradstock KF, Link E, Collins M, et al. A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia. Br J Haematol 2014; 167:618.</a></li><li><a class="nounderline abstract_t">Rotovnik Kozjek N, Kompan L, Soeters P, et al. Oral glutamine supplementation during preoperative radiochemotherapy in patients with rectal cancer: a randomised double blinded, placebo controlled pilot study. Clin Nutr 2011; 30:567.</a></li><li><a class="nounderline abstract_t">Daniele B, Perrone F, Gallo C, et al. Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial. Gut 2001; 48:28.</a></li><li><a class="nounderline abstract_t">Bozzetti F, Biganzoli L, Gavazzi C, et al. Glutamine supplementation in cancer patients receiving chemotherapy: a double-blind randomized study. Nutrition 1997; 13:748.</a></li><li><a class="nounderline abstract_t">Jolfaie NR, Mirzaie S, Ghiasvand R, et al. The effect of glutamine intake on complications of colorectal and colon cancer treatment: A systematic review. J Res Med Sci 2015; 20:910.</a></li><li><a class="nounderline abstract_t">Decker-Baumann C, Buhl K, Frohmüller S, et al. Reduction of chemotherapy-induced side-effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer. Eur J Cancer 1999; 35:202.</a></li></ol></div><div id="topicVersionRevision">Topic 98342 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24140268" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27091810" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27269937" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29545095" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7494232" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8062196" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Chemotherapy-induced lactose intolerance in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15290663" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7799022" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15729427" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy-induced diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10884503" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23963867" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14767748" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The economic burden of supportive care of cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15254061" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Recommended guidelines for the treatment of cancer treatment-induced diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7555436" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Validation of a new measure of diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25186048" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Guidance on the management of diarrhoea during cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15807929" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The assessment and management of cancer treatment-related diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17990113" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A systematic review of diagnostic tests for small intestinal bacterial overgrowth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2312752" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Small intestinal bacterial overgrowth in patients with chronic lymphocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18760593" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Small bowel bacterial overgrowth and lactose intolerance during radical pelvic radiotherapy: An observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23957651" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Review article: small intestinal bacterial overgrowth--prevalence, clinical features, current and developing diagnostic tests, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12728924" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The incidence, pathogenesis and natural history of steatorrhea after bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25728737" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Are bile acid malabsorption and bile acid diarrhoea important causes of loose stool complicating cancer therapy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8353229" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clostridium difficile infection associated with antineoplastic chemotherapy: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8641617" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1497405" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clostridium difficile diarrhea induced by cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9784328" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17023562" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Diarrhea in neutropenic patients: a prospective cohort study with emphasis on neutropenic enterocolitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20862749" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Incidence and risk factors for lower alimentary tract mucositis after 1529 courses of chemotherapy in a homogenous population of oncology patients: clinical and research implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10675076" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10902651" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Colitis and docetaxel-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26490656" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9362174" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Guidelines on acute infectious diarrhea in adults. The Practice Parameters Committee of the American College of Gastroenterology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25786702" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : [Pharmaceutical drugs containing lactose can as a rule be used by persons with lactose intolerance].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19035974" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Quantifying the 'hidden' lactose in drugs used for the treatment of gastrointestinal conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21703817" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Loperamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8508715" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Loperamide. Survey of studies on mechanism of its antidiarrheal activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11804622" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comparison of the peripheral and central effects of the opioid agonists loperamide and morphine in the formalin test in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15357848" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Function of opioids in the enteric nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6382576" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Mechanisms of action of loperamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/589232" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Overdose from Lomotil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/773736" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A double blind crossover comparison of loperamide with diphenoxylate in the symptomatic treatment of chronic diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/123844" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A multicentre double-blind study in acute diarrhoea comparing loperamide (R 18553) with two common antidiarrhoeal agents and a placebo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/123844" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A multicentre double-blind study in acute diarrhoea comparing loperamide (R 18553) with two common antidiarrhoeal agents and a placebo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4611434" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 8: Clinical investigation. Use of a flexible dosage schedule in a double-blind comparison of loperamide with diphenoxylate in 614 patients suffering from acute diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4611433" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 7: Clinical investigation. Efficacy and safety of loperamide in patients with severe chronic diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/330291" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A comparison of lomotil and imodium in acute non-specific diarrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6753707" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A comparative study of loperamide and diphenoxylate in the treatment of chronic diarrhoea caused by intestinal resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7002706" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6989434" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Loperamide, diphenoxylate, and codeine phosphate in chronic diarrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23401037" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17576459" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3306903" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1108754" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Loperamide in the symptomatic control of chronic diarrhoea. Double-blind placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/326642" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Double-blind placebo-controlled study of loperamide (Imodium) in chronic diarrhoea caused by ileocolic disease or resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/773735" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Loperamide: a new antidiarrheal agent in the treatment of chronic diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8348489" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1591068" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Control of chemotherapy-induced diarrhoea with octreotide in patients receiving 5-fluorouracil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7602180" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Diarrhea in terminally ill patients: pathophysiology and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10650901" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8418225" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31432581" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Electrocardiographic changes in loperamide toxicity: Case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31684751" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Loperamide toxicity: recommendations for patient monitoring and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31684751" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Loperamide toxicity: recommendations for patient monitoring and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8532003" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Octreotide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2870957" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Effect of two new antisecretory drugs on fluid and electrolyte transport in a patient with secretory diarrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2888608" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Effect of somatostatin analog on water and electrolyte transport and transit time in human small bowel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2856888" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7799023" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17873499" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11430421" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Control of irinotecan-induced diarrhea by octreotide after loperamide failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11300329" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Octreotide in the treatment of severe chemotherapy-induced diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19902860" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Octreotide in chemotherapy induced diarrhoea in colorectal cancer: a review article.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7628270" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Consensus statement: octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10388084" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Octreotide Acetate in the Treatment of Fluorouracil-Induced Diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8400346" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15160318" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16805331" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26771252" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea: proof of concept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9704727" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10586346" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27622829" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27401247" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27401247" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27401247" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27401247" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30013790" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Uridine triacetate for severe 5-fluorouracil toxicity in a patient with thymidylate synthase gene variation: Potential pharmacogenomic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28950804" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36160401" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Case report: Uridine triacetate in the management of delayed onset 5-fluorouracil toxicity: A case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10340924" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29146401" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32464281" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9537197" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24516038" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15514383" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Phase II study of activated charcoal to prevent irinotecan-induced diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11291056" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17895895" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26051570" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10776974" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18415744" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25503163" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25160493" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25142189" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21733605" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Oral glutamine supplementation during preoperative radiochemotherapy in patients with rectal cancer: a randomised double blinded, placebo controlled pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11115819" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9263281" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Glutamine supplementation in cancer patients receiving chemotherapy: a double-blind randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26759580" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : The effect of glutamine intake on complications of colorectal and colon cancer treatment: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10448260" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Reduction of chemotherapy-induced side-effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
